

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

PURE BIOSCIENCE
Form 10KSB/A
March 10, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-KSB/A

ANNUAL REPORT PURSUANT TO SECTION 13 or 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended July 31, 2003

Commission file number 0-21019

PURE Bioscience
(Exact name of registrant as specified in its charter)

California
(State or other jurisdiction of
incorporation or organization)

33-0530289
(I.R.S. Employer
Identification No.)

1725 Gillespie Way, El Cajon, California 92020
(Address of principal executive offices, including Zip Code)

(619) 596-8600
(Registrant's Telephone Number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock
(Title of Class)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-B is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendments to this Form 10-KSB. ☒

State issuer's revenues for its most recent fiscal year: \$2,589,500

Aggregate market value of the voting stock held by non-affiliates of the registrant: Approximately \$10,123,000 as of October 24, 2003.

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

Indicate the number of shares outstanding of each of the issuer's classes of common stock: 13,854,088 shares of common stock as of February 18, 2004.

Documents incorporated by reference: Certain Exhibits

Explanatory Note on Amendment

This Amendment has been filed to revise the required Sarbanes Oxley certifications Exhibits 31.1, 31.2, 32.1 and 32.2.

PART I

ITEM 1. DESCRIPTION OF BUSINESS

Company Overview

PURE Bioscience (formerly Innovative Medical Services) began as a provider of pharmaceutical water purification products. Although our current revenues are still primarily from the pharmacy industry, we have expanded from our niche pharmacy market into other, broader markets with new products, including residential and commercial water filtration systems, and bioscience products based upon our silver ion bioscience technologies and boric acid based pesticide technologies. Because of this business development evolution, in September 2003, shareholders approved a name change from Innovative Medical Services to PURE Bioscience.

Water Treatment Division

The Fillmaster(R) pharmaceutical water purification, dispensing and measuring products include the Pharmapure(R) water purification system, the FMD 550 dispenser, the patented Fillmaster 1000e computerized dispenser and the patented Scanmaster(TM) bar code reader. We also market proprietary National Sanitation Foundation certified replacement filters for the Fillmaster Systems.

Our Nutripure(R) line of water treatment and filtration systems includes the Nutripure 3000S-Series whole-house water softening systems, the Nutripure Elite reverse osmosis point-of-use systems, the Nutripure 2000 countertop water filtration system and the Nutripure Sport filtered sport bottle. We distribute our various Nutripure products in several ways, including retail sales, catalogue placement, business-to-business sales, internet promotion and in-home sales presentations.

Bioscience Division

Our bioscience division features a patented, aqueous disinfectant called Axenohl(R). A patented new molecule, silver dihydrogen citrate, Axenohl is an electrolytically generated source of stabilized ionic silver that can serve as the basis for a broad range of products in diverse markets. Axenohl liquid is colorless, odorless, tasteless and non-caustic and formulates well with other compounds. Axenohl-based antimicrobial technology is distinguished from competitors in the marketplace because of its superior efficacy combined with reduced toxicity. In March 2003, we obtained Environmental Protection Agency (EPA) registration for our Axen-30(TM) hard surface disinfectant. Axen-30 is a 30-part per million use dilution formula of Axenohl. We plan to pursue additional EPA and FDA regulatory approvals for other applications.

The bioscience division also includes a patent-pending pesticide technology, Triglycylboride(TM) which, like Axenohl, provides effective results without human toxicity and is an alternative to traditional poisons. Triglycylboride has

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

been formulated into EPA approved RoachX(TM) and AntX(TM), the key products in the Company's Innovex(TM) line of pest control products. In addition, the Innovex line features two formulas of EPA-exempt non-toxic TrapX rodent lure, Pro's Choice(TM) caulk for pest control operators, and EPA approved CleanKill(TM), the Axen-based hard surface disinfectant for the pest control industry. The pest control products are being marketed to both commercial pest control and consumer products companies.

History

PURE Bioscience was incorporated in the State of California on August 24, 1992, to pursue the immediate business of manufacturing and marketing the Fillmaster and subsequently a broadly based business of delivering advanced technology, equipment and supplies to not only the pharmacy industry, but also other healthcare markets and to retail consumers.

In the past five years, PURE Bioscience transitioned from a one-product company supplying a niche market to a multi-division company managing new products and programs. In addition to expanding the Fillmaster product line with the Fillmaster 1000e and the Scanmaster, we launched a line of residential water treatment and filtration products. Through acquisition, we have also expanded into the bioscience arena with our Axenohl antimicrobial products and our Innovex pesticide products.

In 1997, we developed and launched the now-patented Fillmaster 1000e computerized, electronic dispenser as an upgrade dispenser to the Fillmaster pharmaceutical water purification and dispensing system.

In 1997 and 1998 we developed our entry-level residential water system, Nutripure(R) NP2000CT. After 18 months of extensive market research, PURE Bioscience completed development of this carbon countertop system and released the product in June 1998.

1

In October 1998, PURE Bioscience acquired AMPROMED, Rio de Janeiro, Brazil, and certain assets of Export Company of America Inc. (EXCOA), Fort Lauderdale, FL, and established a new Nevada corporation to hold and operate the export/import operation. AMPROMED's primary business is the sale of medical, dental and veterinary disposable products. In addition to medical supplies, we plan to distribute water treatment and silver ion products to Brazil through AMPROMED. Since the acquisition, the economic conditions in the region have declined and implementation of the project has been delayed. We no longer have immediate plans to import medical and dental supplies into Brazil but we believe, however, that Ampromed is a vital part of our plan to market and sell Axenohl, RoachX and the Nutripure line of water treatment products.

In 1999 we developed and launched yet another enhancement to our Fillmaster pharmaceutical water purification and dispensing system, the Scanmaster bar code reader. Designed as an add-on upgrade to the Fillmaster 1000e computerized dispenser, the Scanmaster allows the user to scan a prescription's NDC bar code in front of the dispenser, and the Fillmaster 1000e displays the product name and required water quantity. The Fillmaster System then dispenses the prescription with one touch of a button.

Also in 1999, we began investigating marketing opportunities for a silver-ion based technology called Axenohl. The Axenohl patent was owned at the time by NVID International.

Early in 2000, after concluding that we wished to pursue development and marketing of the Axenohl technology, we engaged in a marketing and licensing agreement with NVID International for Axenohl for specific market segments in specific geographic areas.

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

In 2000 we launched the Nutripure Dealer program which expanded our product line to include whole-house water conditioning systems and other point-of-use water treatment equipment while expanding our distribution network by offering these products to independent water treatment for sale to the public under PURE Bioscience's Nutripure brand.

In 2001 we acquired the marketing rights and patent to our boric acid pesticide technologies. The first of these products developed, RoachX, launched in October 2001.

In late 2001, as part of a litigation settlement with NVID regarding the marketing rights to Axenohl, we acquired the patent to the Axenohl technology.

In mid-2002 we expanded our Innovex line of pesticides to include RoachX, AntX75, two formulas of TrapX, Pro's Choice silicone caulk and CleanKill, a hard surface disinfectant for use in the pest control industry that uses Axenohl disinfecting technology.

In 2002 we relaunched the Nutripure Dealer program and changed our Nutripure.com wholly-owned subsidiary to Nutripure Corporation. The corporation is now being used to operate the Nutripure Dealer program.

In March 2003, we received Environmental Protection Agency (EPA) registration for our new Axen-30 formulated Category IV hard surface disinfectant product for commercial, industrial and consumer applications. Axen-30 is a 30-part per million (ppm) use-dilution formula of our patented antimicrobial technology, Axenohl. The additional EPA approval allows us to expand the existing Axen efficacy claims as a hard surface disinfectant to include a 30 second kill time on standard indicator bacteria, a 24 hour residual kill on standard indicator bacteria, a 2 minute kill time on some resistant strains of bacteria, 10 minute kill time on fungi, 30 second kill time on HIV Type I, and 10 minute kill time on other viruses. These claims distinguish the efficacy of Axen-30 from many of the leading commercial and consumer products currently on the market, while maintaining lower toxicity ratings.

In July 2003 we received a second United States patent granted for the unique disinfectant Axenohl. United States patent 6,583,176 was issued on June 24, 2003 and covers the formulation of the Axenohl aqueous disinfectant in combination with ethyl alcohol. United States patent 6,583,176 is a division of the first United States patent 6,197,814 issued on March 6, 2001 covering the basic Axenohl formulation and the method of making.

In September 2003, PURE Bioscience announced the first significant commercialization of its hard surface disinfectant, Axen-30(R), which is sold by EnvirOx L.L.C. of Danville, Illinois, as Critical Care(TM), a new commercial disinfectant-fungicide-virucide.

Also in September 2003, the Company announced an agreement with Therapeutics, Inc., a drug development company based in La Jolla, California, for the development and commercialization of Food and Drug Administration (FDA) regulated Axenohl-based products. Therapeutics, Inc. will fund and direct all development activities and FDA regulatory filings and will initially focus on development of Axenohl-based products for the treatment of bacterial, viral and fungal mediated diseases and conditions.

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

WATER TREATMENT DIVISION

Pharmaceutical Water Treatment

Fillmaster(R) The Fillmaster dispensing apparatus, connected to the Pharmapure(R) reverse osmosis water filtration system, provides measured amounts of purified water for reconstitution of liquid oral antibiotics and certain other pharmacy applications. Pharmapure is a six-stage water purification unit featuring an electronic water purity testing module and an auxiliary faucet for dispensing purified water. Fillmaster is a calibrated volumetric measuring and dispensing apparatus. The entire system (the "Fillmaster System") integrates with the building's tap water plumbing and is closed and pressurized to prevent contamination.

The Fillmaster System saves time and money for pharmacies. According to our testing, the Fillmaster has a fill rate at least three times that of previous bottle-and-hose methods, and direct and indirect costs associated specifically with bottled water are reduced or eliminated. Pharmacy storage space can be reallocated to more profitable items, labor savings accompany the efficiencies, and the expense of bottled water purchases of up to \$1.25 per gallon is replaced by one annual filter change. Under optimum usage, a pharmacy reduces the cost of "purified water" to approximately \$.04 per gallon.

In addition to efficiency and cost savings, the Fillmaster System increases prescription integrity by greatly reducing the possibility of human error while dispensing prescriptions. The patented Fillmaster 1000e employs multiple microprocessors to provide accurate and even-flow dispensing. We sell Fillmaster 1000e dispensers as an upgrade to existing installations and as a component of new installations. The Scanmaster, launched in August 1999, is a pager-sized, modular upgrade to the Fillmaster 1000e. A user simply scans a prescription's NDC bar code in front of the dispenser, and the Fillmaster 1000e displays the product name and required water quantity. The Fillmaster System then dispenses the prescription with one touch of a button. The advanced technology of the Fillmaster 1000e computerized dispenser and the Scanmaster bar code reader ensures accuracy of measurement and assurance of compliance to minimize liability.

This is a finite, niche market in which our significant customers to date consist primarily of domestic retail chain pharmacies. There are approximately 72,000 pharmacies in the United States and Canada, with many thousands more worldwide. Water-mixed antibiotic prescriptions, for which the Fillmaster is primarily used, make up approximately 12.6% of a pharmacy's total prescriptions and approximately 20% of a pharmacy's gross profit. We have installed over 22,000 Fillmaster dispensers in pharmacies across the nation, including Wal-Mart, Walgreens, Albertson's/American Stores, Eckerd, Fred Meyer, Target, CVS, Kroger, Smith's Food and Drug, Longs Drugs, Rite-Aid, Drug Emporium, Fry's, Hi-School Pharmacies, H-E-B, Fleming, Giant and Snyders. Also included in the customer base are many United States Military Clinics, including Bethesda Naval Hospital; the Kaiser Foundation for Medical Care; the Mayo Clinic and several hundred Independent and Hospital Pharmacies.

Fillmaster(R) System Filters We also market unique and proprietary NSF certified filter replacements for the Fillmaster's Pharmapure water purification system, which require changing at intervals of approximately 12 months or sooner as indicated by the purity testing module. The filter replacements represent a significant continuing source of revenues to us.

Customer Service Plan 2000(TM) PURE Bioscience offers outstanding service to its pharmacy customers with its exclusive Customer Service Plan 2000 (CSP 2000). The CSP 2000 provides an extended unlimited warranty on all PURE Bioscience's pharmacy products, regardless of age or quantity; significant discounts on maintenance item costs; free software upgrades for the Fillmaster 1000e and Scanmaster; a secure web site that allows pharmacy customers to monitor history, scheduled maintenance and account status; automatic replacement filter

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

shipments; and simplified, annual invoicing. Motivated by the cost savings and the extended warranty coverage, most of our chain customers have entered into multi-year contracts for the CSP 2000.

Residential Water Treatment PURE Bioscience's Nutripure Water Dealer Program offers existing independent water treatment dealers a line of residential water softening and other point-of-use water treatment equipment for sale to the public under PURE Bioscience's Nutripure brand. In addition, the program provides complementary, industry-unique financing that extends credit to consumers for the purchase of water treatment equipment from participating dealers. We realize revenues from both the sale of Nutripure equipment and the financing.

3

The Nutripure whole-house water softening systems, like most water softening systems on the market, are typically professionally installed in a customer's basement or garage and require electricity. The Nutripure water softening systems, comprised of a resin tank, brine tank and controller, extract minerals from the water through an ion exchange process. Nutripure whole house systems are often installed in conjunction with Nutripure reverse osmosis systems.

We have formed alliances with independent dealer groups, finance companies and leading equipment component manufacturers to create a marketing program to sell and finance whole-house water treatment systems through existing dealers. We believe this marketing strategy provides consumers and independent dealers a name and image they can trust. The programmable systems come equipped with microprocessors and electronic water meters to monitor daily water usage and provide automatic, demand-based water conditioning. An electronic memory stores operating system information, and battery backup keeps it current if power is lost.

PURE Bioscience's Nutripure Water Dealer Program also offers a Nutripure line of residential drinking water systems that combines reverse osmosis technology with carbon filtration to improve the taste, smell, quality and safety of standard tap water. Reverse osmosis is a water treatment process that removes contaminants from water by using pressure to force the water molecules through a semi-permeable membrane. Carbon, sometimes referred to as activated carbon, is a water treatment medium commonly used for dechlorination and for reducing trace and soluble materials from water. We also market unique and proprietary filter replacements for the Nutripure residential drinking water systems that require changing every 12 months.

The Nutripure reverse osmosis filtration system is comprised of a storage tank, a faucet and a water filtration apparatus which includes a sediment filter, pre- and post-carbon filters and a reverse osmosis membrane. Nutripure requires neither professional installation nor electricity to operate. The Nutripure system filters to .001 micron and reduces heavy metals, chemicals and microorganisms, such as cryptosporidium and giardia, as well as reducing bad taste and odor from drinking water. A micron is a measurement unit equal to one millionth of a meter. Micron measurements are applied to water filtration systems to indicate the particle size at which suspended solids larger than that size will be removed.

Nutripure(R) 2000 PURE Bioscience entered the retail venue with its Nutripure 2000 Countertop Water Filtration System. Nutripure 2000, developed specifically for mass merchandising, offers water filtration technology at competitive pricing. Nutripure's filter component is a one-micron, carbon microfilter that reduces dirt, chemicals, lead and parasites to improve the taste, quality and safety of tap water. The Nutripure 2000 requires no assembly, mounts directly to a faucet and features a 2,000-gallon capacity filter, an automatic bypass

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

shutoff valve, an electronic monitor that reminds users when to change the filter, and an exclusive filter design that prevents leaking and contamination because water flows only through the completely sealed filter cartridge. We distribute Nutripure 2000 through retail outlets in the United States.

The filter component, manufactured by Omnipure Filter Company of Caldwell, Idaho, has been tested by Spectrum Laboratories to meet or exceed National Sanitation Foundation Standard No. 53 Health Effects and Standard No. 42 Aesthetic Effects. These tests determine if the product meets the most stringent standards set by the NSF for consumer water filtration. Spectrum Labs, Inc. is an independent laboratory in New Brighton, Minnesota. The testing on the Nutripure product was paid for by Omnipure Filter Company, Caldwell, Idaho. The test reports were submitted by Spectrum Labs, Inc. to Omnipure on April 6, 1998. We had no prior relationship with Spectrum Labs when the tests were conducted. We selected the Omnipure filter component for the Nutripure 2000 in part because it had this testing available, though there are several other similar quality filter components readily available. Other than purchase orders there is no written agreement between us and Omnipure.

Spectrum Labs' Product Testing Department conducted testing on the product for chlorine reduction in accordance with test protocol contained in NSF International Standard Number 42 "Drinking Water Treatment Units/Aesthetic Effects," Appendix B, "Chemical Unit Test Methods," Section I, "Procedure - Plumbed-In and Faucet Mounted Taste, Odor and Chlorine Reduction Units Without Reservoir," revised June 1988. The product was found to meet the requirements for compliance under Standard Number 42 for taste, odor and chlorine reduction for Class I filters.

In addition, Spectrum Labs evaluated the product for cyst and turbidity reduction and structural integrity in accordance with test protocol contained in NSF International Standard Number 53, "Drinking Water Treatment Unites/Health Effects," Section 6.12, "Mechanical Filtration Test Methods," and Section 6.6, "Structural Integrity Performance. The filter media evaluation was performed based on test protocol contained in NSF Standard Number 53, Section 6.7, "Filter Media." Influent and effluent samples were analyzed for cyst reduction using American Society for Testing and Materials Method Number F796 which is a standard particle counting method. Samples evaluated for turbidity were analyzed using EPA Method Number 180.1 which is a nephelometric method. NSF Standard Number 53, Section 6.6.1.2 protocol was used to perform the pressure evaluation for structural integrity. The product was found to meet the requirements for compliance under NSF Standard Number 53 for cyst and turbidity reduction, filter media evaluation and structural integrity performance.

4

Nutripure(R) 2000 Replacement Filters We also market replacement filters for the Nutripure 2000 water system. The Nutripure 2000 contains a 2,000-gallon filter that must be changed every year.

Nutripure(R) Sport Filtered Sport Bottle The Nutripure Filtered Sport Bottle, also offered as a private label or premium item, provides clean, great-tasting water for on-the-go consumers. The Nutripure Filtered Sport Bottle features a small carbon filter at the bottom end of the plastic straw so that, as the consumer drinks through the straw, the water is drawn up through the filter. An innovative alternative to buying expensive bottled water, Nutripure Sport filters an average of approximately 30 microns, reducing sediment and chlorine, and can be refilled 60 times before an inexpensive filter change is required. The Nutripure Sport program provides recurring revenue through sales of the replacement filter twin pack.

RETAIL PRODUCTS DIVISION

Medifier(TM) We also market the Medifier, a patented universal prescription

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

bottle label magnifier. The Medifier holds various sized prescription bottles in position under a magnifier strip that enlarges dosage and use instructions to a clearly readable size. The Medifier is marketed to PURE Bioscience's existing sales channels, as well as through catalogue sales and promotional products distributors.

BIOSCIENCE DIVISION

Our bioscience division features a patented, aqueous disinfectant called Axenohl(TM). Based on the EPA toxicity categorization of antimicrobial products that ranges from Category I (high toxicity) down to Category IV, Axen, with its combination of the biocidal properties of ionic silver and citric acid, is an EPA Category IV antimicrobial for which precautionary labeling statements are normally not required. This compares with Category II warning statements for most leading brands of antimicrobial products.

The initial EPA registration for use of Axenohl and Axen (12-parts per million formula) as hard surface disinfectants was issued in 2001. In March 2003, we received Environmental Protection Agency (EPA) registration for our new Axen-30(TM) formulated Category IV hard surface disinfectant product for commercial, industrial and consumer applications. Axen-30 is a 30-part per million (ppm) use-dilution formula of our patented antimicrobial technology, Axenohl(TM) (silver dihydrogen citrate).

The recent EPA approval allows us to expand the existing Axen efficacy claims as a hard surface disinfectant to include a 30 second kill time on standard indicator bacteria, a 24 hour residual kill on standard indicator bacteria, a 2 minute kill time on some resistant strains of bacteria, 10 minute kill time on fungi, 30 second kill time on HIV Type I, and 10 minute kill time on other viruses. These claims distinguish the efficacy of Axen-30 from many of the leading commercial and consumer products currently on the market, while maintaining lower toxicity ratings.

The tests conducted to obtain the recent EPA approval were performed by nationally recognized independent laboratories Nelson Laboratories of Salt Lake City, Utah and AppTec ATS, St. Paul, Minnesota, under AOAC protocol and GLP regulations in accordance with EPA regulations. Specific Axen test results include:

- o 30-Second Kill Time ---At 30 ppm, Axen demonstrated a 30-second, 99.9999% kill of standard indicator organisms including Staphylococcus aureus ATCC 6538, Pseudomonas aeruginosa ATCC 15442 and Salmonella choleraesuis ATCC 10708. Each is regarded as ever present in nearly every person's life and is also a frequent human pathogen.
- o Residual Kill Activity --- The residual activity of Axen was tested at 0, 1, 6, and 24 hours after application to a hard surface against standard indicator organisms (Staphylococcus aureus ATCC 6538, Pseudomonas aeruginosa ATCC 15442 and Salmonella choleraesuis ATCC 10708). Quantitative residual results at 24 hours after initial application show a 99.99% reduction in all three bacteria tested.
- o Bacteria---Additional testing of Axen against Methicillin Resistant Staphylococcus aureus ATCC 700698 (MRSA), Vancomycin Resistant Enterococcus faecium ATCC 700221 (VRE) and Escherichia coli OH157 ATCC 43888 demonstrated a 99.9999% kill in 2 minutes. These specific bacteria are especially problematic in hospitals because of their resistance to antibiotics. Further, Axen showed a 99.9999% kill in 30 seconds against Listeria monocytogenes ATCC 19111. Food processing operations are challenged to keep this bacterium under control.

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

- o Fungus --- Axen demonstrated a 99.9999% kill in 10 minutes of the common athlete's foot fungus, *Trichophyton mentagrophytes* ATCC 9533. This data allows the Company to add a fungicidal claim to its hard surface disinfectant label.
- o Viruses --- Axen also demonstrated 99.9999% virucidal efficacy against HIV Type 1 in 30 seconds, Herpes simplex virus type 1 in one minute, and Influenza A virus ATCC VR-544, Rhinovirus type R 37 ATCC VR-1147, Strain 151-1 and Poliovirus type 2 ATCC VR-1022, Strain Lansing in 10 minutes. After review and approval by the EPA, this data allows the Company to add these virucidal claims to its hard surface disinfectant label.

In September 2003, PURE Bioscience announced the first significant commercialization of its hard surface disinfectant, Axen-30(R), which is sold by EnvirOx L.L.C. of Danville, Illinois, as Critical Care(TM), a new commercial disinfectant-fungicide-virucide.

We plan to pursue additional EPA and FDA regulatory approvals for other applications. Additional possible uses for this product include wound care, topical infection care, personal disinfecting retail products, food processing, and food safety applications which may require FDA approvals, as well as municipal water treatment and point-of-use/point-of-entry water treatment products, which may require additional EPA approvals.

Also in September 2003, the Company announced an agreement with Therapeutics, Inc., a drug development company based in La Jolla, California, for the development and commercialization of Food and Drug Administration (FDA) regulated Axenohl-based products. Therapeutics, Inc. will fund and direct all development activities and FDA regulatory filings and will initially focus on development of Axenohl-based products for the treatment of bacterial, viral and fungal mediated diseases and conditions.

Our bioscience division also includes a line of pesticide technologies. Branded as Innovex(TM), the product line launched in October 2001 with our EPA-approved, patent-pending RoachX(TM). Subsequently, we have developed and launched additional products in the Innovex product line, including the EPA-approved AntX75(TM), two formulas of EPA-exempt non-toxic TrapX rodent lure, Pro's Choice(TM) caulk for pest control operators, and EPA approved CleanKill(TM), the Axen-based hard surface disinfectant for the pest control industry.

United States Department of Agriculture testing confirms that RoachX is over 96% effective in three to four days with one application for indoor and outdoor eradication of cockroaches, and can be used near children and food preparation areas. Boric acid is a well-known and effective deterrent of cockroaches and will kill them on contact, but cockroaches do not naturally eat the repellent. Although many pesticide products contain boric acid as the listed active ingredient, we believe RoachX to be new because of the endothermic reaction caused by the combination of boric acid and polyglycol that produces three unique results: 1) The formula protects the boric acid from water and humidity, 2) When combined with an attractant, the cockroaches perceive the formulation as food and will actually eat the polyglycol-encapsulated boric acid, and 3) The formula acts as a time-released pesticide, allowing the cockroach to return to the nest before it dies and then becomes a "bait station" for other roaches in the colony. We believe the product line, containing particular formulas and attractants for specific pests, is effective against cockroaches, ants, palmetto bugs, silverfish, waterbugs, ticks, fleas, lice and garden pests.

Like the Axenohl antimicrobial technology, the boric acid based pesticides are very competitive with regard to efficacy when compared to leading brands while maintaining lower toxicity ratings.

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

PURE Bioscience is currently maintaining its initial strategy of marketing its Innovex pest control product line to industry wholesalers, but the Company is in the process of significantly expanding its marketing reach. The Company has taken a high level, executive-to-executive approach with leading national pest control companies, including the two largest companies in this sector which, as of the date of this report, are both evaluating the product line. The Company has also launched an aggressive marketing program to directly target individual pest control operators to either sell directly or create a grass roots demand from pest control professionals for the products to be carried by their distributors. As a final measure to maximize market reach, the Company plans to offer a private label program which should fortify sales to pest control professionals as well as provide a cost-effective entry into the consumer retail marketplace. The company believes the competitive advantages of these products should allow favorable outcomes from both of the additional marketing strategies.

Competition

Although we have only one known competitor in our pharmaceutical water purification market, we face very strong competition in the residential water treatment markets where many large, long-established competitors currently hold

6

most of the market share and have the capital resources available to invest in large national marketing campaigns. The market for Axenohl is highly competitive because we must work to displace traditional disinfecting technologies sold by well-known international industry leaders.

The market is similar for our pesticide products. Although recent changes in EPA regulations may ease our ability to enter the market, ongoing strong market presence of existing pesticide companies may make it difficult to compete. On June 8, 2000, the United States EPA reclassified the Dow Chemical product Dursban (also sold as Lorsban). Over 800 products containing the organophosphate pesticide chlorpyrifos are reclassified and now may only be sold in a significantly diluted form. Sales of original, stronger formulations of such products to retailers ended February 1, 2001, and retailers must remove the products from shelves by December 31, 2001. The current formulations are also banned for commercial and agriculture professionals as of December 31, 2000. Professional pest control companies must use a 100 to 1 diluted version of the current product strength and obtain a waiver of responsibility from the home or business owner. As of June 6, 2001, the product underwent a further 10 to 1 dilution, creating a 1000 to 1 diluted treatment.

Our ProChoice caulk, a companion product to our pesticide products, is a repackaged readily available food-grade silicone caulk manufactured by General Electric. Although competition is significant because the caulk is commercially available from multiple manufacturers in standard 10-11 ounce tubes, we have repackaged it for the convenience of our customers into 4 ounce tubes that fit bait guns used by the pest control operators.

We recognize that innovative marketing methods are required in such competitive markets. We work to focus on the high quality and value price of our products in their markets.

Patents and Intellectual Property

We own patents on the Medifier, the Fillmaster 1000e Electronic Dispenser and the Axenohl technology. In addition, we have a patent application pending for RoachX and related pesticide products. Except for the Nutripure whole-house water treatment systems, our other water treatment products are comprised of combinations of our own proprietary components, custom made components and patented, off-the-shelf components and are assembled and packaged by us. The

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

Nutripure whole-house water treatment systems sold through the Nutripure dealer program are purchased from a variety of manufacturers as private label products for PURE Bioscience. These manufacturers use patented key components in their products.

The Medifier patent, which expires in March 2010, protects a device for use as a magnifying implement which has a housing member designed to accommodate prescription bottles of various popular sizes therein in a fixed position. A longitudinally moveable magnifying lens slideably mounted in the housing member is utilized to magnify the print contained on an instruction label located on the side of the prescription bottle. Alternate embodiments allow different size medicine bottles to be alternately mounted in concentric fashion, or with the side of the medicine bottles facing the lens in a fixed position.

The Fillmaster 1000e patent expires in August 2017 and protects a method and apparatus for dispensing fluids in response to a user request for a specified amount of the fluid. A microprocessor opens and closes a fluid port for predetermined amounts of time to control the amount of fluid dispensed. The microprocessor monitors the elapsed time and the amount of fluid that has been dispensed since the last time the filter was serviced. In one preferred embodiment, the amount of fluid that is dispensed is measured by continuously monitoring the volume of fluid flowing through the apparatus. A pressure measurement device allows the microprocessor to monitor the fluid pressure. The microprocessor prevents fluid from being dispensed if the pressure is not within a predetermined range of tolerances. The fluid port is opened and closed by activating and deactivating a solenoid. A keypad allows the user to input the amount of fluid that is to be dispensed. A "Wait" period is imposed between the time that the user initiates the first stage and the time the user may initiate the second stage. The microprocessor does not open the fluid port if a "Failure" condition exists. An LCD is provided to display the amount of fluid that the user has requested. In an alternative embodiment, a bar code scanner or other input device allows the user to automatically input the amount of fluid that is to be dispensed.

On November 30, 2001, the Company acquired the patent for Axenohl, a silver ion based technology and its method of making which is the basis for the Company's silver ion products. The Company previously licensed the use of this patent.

The Company purchased the patent for 700,000 shares of its common stock plus certain expenses. The Company valued the patent at \$1,540,600 based on the market price of the stock exchanged. In addition, the Company agreed to pay royalties in the amount of 5% of gross Axenohl sales until March 2018, the end of the life of the patent. There are minimum royalties due of \$1,000,000 for the

7

period of November 2001 to July 31, 2004 and for each fiscal year thereafter. PURE Bioscience has the right, in its sole and absolute discretion, to pay the minimum royalty in cash or in common stock at prevailing market prices. If the Company determines it does not wish to pay the minimum royalty payment, it has the option at any time to transfer the patent back to the prior owner rather than pay the minimum royalty.

The United States patent for Axenohl was issued on March 6, 2001, and a supplemental patent has been filed to cover the substitution of 14 other organic acids for citric acid in the formulation.

In June 2003, we received a second United States patent granted for Axenohl that covers the formulation of the Axenohl aqueous disinfectant in combination with ethyl alcohol. In addition, the Company has received national patents in Australia and New Zealand as well as regional patents in the Eurasian and OAPI

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

regions of the world. National patent applications are now pending in Brazil, Canada, China, Japan and Mexico as well as the European and the ARIPO regions of the world. The Axenohl International Patent Application was published by the World Intellectual Property Organization (www.wipo.org) on April 22, 1999 under publication Number WO 99/18790.

A patent application for RoachX and related products was filed in February 1998 to protect a nonaqueous form of insecticide consisting of a desiccant, preferably boric acid, with additional ingredients for binding, stability and target insect attraction.

Manufacturing

The Fillmaster and Nutripure water systems are assembled in our manufacturing facility at our corporate offices primarily from custom manufactured components. It is our goal to perform minor manufacturing in our facility to minimize wages, equipment expense and insurance. No components of the systems have permanent or unequivocally restricted availability. Many manufacturers are available to produce the components, and a change in suppliers would result in virtually no lost production.

The original Fillmaster dispenser and the new Fillmaster 1000e dispenser are both assembled in our manufacturing facility at our corporate offices mostly from proprietary and custom parts fabricated to our specifications from injection-molded plastic and fabricated acrylic.

The Nutripure Sport bottle is also assembled in our manufacturing facility at our corporate offices from proprietary and custom components manufactured under exclusive agreements with several different manufacturers. Alternative manufacturers exist, and a change in suppliers would result in virtually no lost production. There are no plans to alter production methods.

We manufacture RoachX, AntX and TrapX in our manufacturing facility at our corporate offices and outsource some of the packaging functions. The active and inactive ingredients of these products are readily available through multiple manufacturers in the US and abroad.

We purchase caulk manufactured by General Electric for our ProChoice product from a General Electric authorized distributor and repackager. This caulk is readily available through several other manufacturers.

We blend the Axenohl products in our manufacturing facility at our corporate offices from concentrate produced by our subsidiary, ETI-H2O. Silver, the primary active ingredient, is a readily available commodity, and the other active and inactive ingredients of Axenohl are readily available from chemical supply companies.

We purchase water softening and filtering equipment from a variety of manufacturers for the Nutripure water dealer program which they produce and label as Nutripure equipment. We resell to participating water treatment equipment dealers.

Research and Development

Research and Development costs that have no alternative future uses are charged to operations when incurred and are included in operating expenses. The total amounts charged to Research and Development expense were \$981,500 and \$780,500 in the fiscal years ended July 31, 2003 and 2002, respectively.

Employees

As of October 24, 2003, PURE Bioscience employed twenty-six people, all of whom are full-time individuals: seven employees in product assembly and shipping, five employees in sales, marketing and customer service, five employees in research and development and eight employees in management and administration.

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

We choose to outsource more expensive, specialized functions including public relations and selected engineering projects.

8

ITEM 2. PROPERTIES

Our business operates in a 13,067 square foot facility located in a light industrial/office park in El Cajon, California. This location houses all administrative, executive, sales, assembly, shipping and manufacturing functions. The space is leased from an unaffiliated third party under a sixty-five month agreement commencing on July 1, 1996. The monthly rental is \$0.80 per square foot plus \$0.15 per square foot for maintenance of common areas. There is also a fixed yearly increase of 4%. We have also signed an amendment to the lease and exercised an option to lease the building for an additional five years.

ITEM 3. LEGAL PROCEEDINGS

The following is an update of developments in the previously disclosed litigation involving PURE Bioscience filed in the Circuit Court of Pinellas County, Florida by Zedburn Corporation, against us for breach of contract in October 1997. The breach of contract alleged was for payment of fees for Mr. David Reitz's and Mr. Steven Durland's services of arranging a public offering of our common stock. We have filed counterclaims based upon the Racketeer Influenced and Corrupt Organization (RICO) Act against David Reitz, Zedburn Corporation, Capital Development Group, Steven Durland and other defendants. It is our position that Mr. Reitz and others perpetrated a scheme to defraud us of cash fees and securities in connection with purported services of arranging a public offering of our common stock. In October 1997, Mr. Reitz and Zedburn filed for protection under the Federal bankruptcy laws. In August 1998, Mr. Reitz voluntarily dismissed his bankruptcy and as a result thereof we have named Mr. Reitz as a defendant to our counterclaims.

We believe that the defendants had perpetrated similar schemes against other parties. We also believe we have substantially completed discovery and compiled compelling evidence to prove our claims.

Several of the Defendants filed Motions to Dismiss our counterclaims. A hearing on the Motions was held on October 1, 1998. Certain of the Motions were granted pending our amendment of our Counterclaim. We amended our Counterclaims in accordance with the judge's rulings. Certain Defendants filed second Motions to Dismiss the amended Counterclaims. A hearing on these latest motions was held in March 1999, before a different judge than the judge who ruled on the first motions. On April 20, 1999, orders were entered granting the Defendants' Motions to Dismiss. However these Orders did not state the basis for the Orders, nor was our legal counsel provided notice of the Orders or a copy of the new judge's correspondence offering a "formal ruling" upon request. In May 1999, we filed an Appeal of the Orders and Motions for Reconsideration based upon inconsistency of the Orders with the previous judge's rulings and the lack of notice to us. In August 2001, the Court of Appeals reversed the trial court's ruling and reinstated our claim against the defendants with the exception of PURE Bioscience's RICO action. We intend to pursue a trial as soon as possible. On September 5, 2003 the Circuit Court for Pinellas County, determined this case is appropriate for mediation, and ordered the parties to attend mediation.

On August 8, 2002, Billy Stapleton and Susie Stapleton filed a complaint for patent infringement in the United States District Court Eastern District of Tennessee at Knoxville, against PURE Bioscience' product RoachX. On August 12, 2002 Billy and Susie Stapleton filed an amended complaint. On May 2, 2003 PURE Bioscience filed its answer to amended complaint, denying allegations generally and specifically, and stating nine affirmative defenses to the amended complaint. PURE Bioscience believes Stapleton's amended complaint is frivolous

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

and without merit.

We have neither accrued a liability in our financial statements regarding this litigation nor disclosed the matter in the footnotes thereof. We have not done so because we do not believe there is any merit to Mr. Reitz's claims and that the likelihood that we will realize a loss from these matters is believed remote. In addition, we believe that in the unlikely event that we settle, the amount of any such settlement would not be material to our financial statements.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted to shareholders in the fourth quarter of the fiscal year.

PART II

ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

- (1) Market Information: PURE Bioscience's common stock is traded on the NASDAQ SmallCap Market under the symbol "PURE".
- (2) High and Low Bid Prices: The following table sets forth high and low bid prices for each fiscal quarter, as reported by NASDAQ, for the last two fiscal years. Such quotations represent inter-dealer prices without retail mark-ups, mark-downs, or commissions and, accordingly, may not represent actual transactions.

Fiscal 2003			Fiscal 2002	
Quarter Ended	High	Low	Quarter Ended	High
July 31, 2003	\$0.98	\$0.56	July 31, 2002	\$1.76
April 30, 2003	\$1.10	\$0.55	April 30, 2002	\$2.29
January 31, 2003	\$1.23	\$0.26	January 31, 2002	\$2.55
October 31, 2002	\$0.82	\$0.25	October 31, 2001	\$3.47

- (3) Security Holders: As of October 24, 2003, we had approximately 172 holders of record of our common stock. This does not include beneficial owners holding common stock in street name. The closing price per share on October 24, 2003 was \$0.80.
- (4) Dividend Plans: We have paid no common stock cash dividends and have no current plans to do so.
- (5) Preferred Stock: There are no shares of preferred stock presently outstanding.
- (6) Changes in Securities: During the fourth quarter of the fiscal year, we conducted a \$60,000 private placement in which the Company issued 120,000 shares of common stock to three accredited investors at a price of \$0.50 per share. With respect to the sales made, we relied on Section 4(2) of the Securities Act of 1933, as amended. No advertising or general solicitation was employed in offering the securities. The securities were offered solely to accredited or sophisticated investors who were provided all of the current public information available on PURE Bioscience.
- (7) Securities Authorized for Issuance under Equity Compensation Plans

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)	Weighted-average exercise price of outstanding options, warrants and rights (b)	Number of securities remaining after exercise of outstanding options, warrants and rights (c)
Equity compensation plans approved by security holders	3,129,375	1.86	
Equity compensation plans not approved by security holders	1,015,000	1.63	
Total	4,144,375	1.83	

The following equity compensation plans were not approved by security holders:

1. 2001 ETIH2O Stock Option Plan: Adopted by the Board in January 2001 with 1,000,000 shares authorized under this Plan. The options have a five-year term with vesting ratably over a five-year period.
2. 2001 Consultants and Advisors Stock Option Plan: Adopted by the Board in January 2001 with 500,000 shares authorized under this Plan. The maximum number of shares subject to options granted under this Plan to any one participant shall not exceed 50,000 shares in any 12-month period. The options have a five-year term with vesting ratably over a five-year period.
3. Executive Officers and Directors are not eligible participants under these plans.

ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Except for the historical information contained herein, the following discussion contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ substantially from those referred to herein due to a number of factors, including but not limited to risks described in the section entitled Competition and elsewhere in this Form 10KSB. Our consolidated financial data includes Export Company of America, Inc., Ampromed Comercia Importacao e Exportacao Ltda., ETI-H2O Corporation, and Nutripure Water Corporation. The following discussion and analysis should be read in conjunction with the audited financial statements of PURE Bioscience.

Results of Operations for the Year Ended July 31, 2003 Versus Year Ended July 31, 2002 During the year, we continued to realize revenues from multiple product lines in our different divisions. In order to be more informative regarding distribution of revenues, discussion of revenues will be in terms of our water

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

treatment segment and our bioscience segment, which includes silver ionization and pesticide divisions.

Revenues of \$2,589,500 in the year ended July 31, 2003 were 19% lower than the \$3,206,400 in revenues reported for the year ended July 31, 2002. The decrease was due to a decrease in sales in the biosciences division. During the year, water treatment division revenues of \$2,473,800 were 13% higher than the \$2,188,900 in the prior year. Bioscience segment revenues in the current year of \$115,700 were 89% lower than the \$1,017,500 in the prior year and reflect a large decrease in both silver ionization and pesticide product sales.

The increase of \$284,900 in water treatment division revenues was comprised of an increase of \$116,000 in Fillmaster pharmaceutical water system replacement filter sales, an increase of \$48,800 in Residential Water Treatment sales and an increase of \$120,100 in the Nutripure dealer program revenues. Fillmaster pharmaceutical water system sales remained unchanged at approximately \$1,160,700 from the prior year; however, at July 31, 2003 the Company had a backlog of Fillmaster systems of \$273,400. The market continues to be very competitive, and we expect revenues from our commercial/retail water treatment products to continue their historic steady growth.

The decrease in pesticide product sales was due to the change in sales strategy implemented earlier this year, including a change from salaried sales employees to commissioned outside sales representatives. During the year, we refocused our market strategy from marketing primarily to the pest control industry wholesalers to include marketing directly to major industry leaders. The change in sales and marketing strategy resulted in a decrease in sales as we restructure the pesticide division to more effectively target the professional pest control industry's need for highly effective but least toxic pest control products. We believe that our restructuring will result in increased sales, but we recognize that we face significant competition from larger, better capitalized companies in this market. We expect to see a shift toward increasing pest control product sales in the coming year.

The decrease in silver ionization sales was solely due to lack of sales of Axen to Dodo & Company. In March 2001, we signed a five-year contract to provide Axenohl to Dodo & Company, a Korean cosmetics manufacturer and marketer. During prior fiscal year, Dodo & Company expanded its A-Clinic Club line to include over 10 different products, all of which contain Axenohl as an active ingredient. Because of Dodo & Company's significant investment in the product line, we believed we would be able to renegotiate the contract to the satisfaction of both parties; however, in early December 2002, we were informed by the Chairman of Dodo & Company that Dodo & Company has begun a bankruptcy reorganization process. We have not yet renegotiated the contract but have resumed incremental shipments to Dodo & Company on a pre-paid, ex-factory basis.

The antimicrobial market is highly competitive, and we anticipate that market acceptance of a brand new technology may be a long term achievement. In addition to competition challenges, we believe that the investment necessary to pursue research testing and regulatory approval for Axenohl products will continue to be significant. As we receive additional regulatory approvals for Axenohl, however, we expect revenues to develop quickly. For example, now that we have received EPA approval on Axen-30(R), our Axenohl-based hard surface disinfectant, and we expect to see a shift toward increasing Axenohl division product sales in the coming year, and we believe that sales of Axen-30 will have a significant impact on revenues in future.

For example, in September 2003, PURE Bioscience announced the first significant commercialization of its hard surface disinfectant, Axen-30(R), which is sold by EnvirOx L.L.C. of Danville, Illinois, as Critical Care(TM), a new commercial disinfectant-fungicide-virucide,

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

Also in September 2003, the Company announced an agreement with Therapeutics, Inc., a drug development company based in La Jolla, California, for the development and commercialization of Food and Drug Administration (FDA) regulated Axenohl-based products. Therapeutics, Inc. will fund and direct all development activities and FDA regulatory filings and will initially focus on development of Axenohl-based products for the treatment of bacterial, viral and fungal mediated diseases and conditions.

We continue to believe that pesticide technologies will have a material impact on revenues in the coming year, and we continue to believe that the silver ion technologies will ultimately become the largest revenue generator for PURE Bioscience.

Gross profit for the year ended July 31, 2003 was \$1,055,500 versus \$1,607,900 in 2002. Gross profit percentage of 41% in 2003 was lower when compared to 50% in 2002 because of the decrease in Axenohl sales associated with higher margins and the increase in Nutripure dealer program revenues which have proportionally lower margins.

10

Net loss from for the year ended July 31, 2003 was \$3,284,000 versus net loss of \$2,222,500 for the same period in 2002. During the year, General and Administrative expenses increased \$154,200, or 8%, from \$2,027,900 at in fiscal 2003 versus \$2,182,100 in fiscal 2002. Administrative expenses include an increase in amortization costs associated with purchased patents and licenses. Selling expense decreased approximately \$283,100, or 38%, from \$749,300 in 2002 to \$466,200 in 2003 because of a decreased use of salaried sales personnel and an increase in the use of commissioned salespeople. Research and Development increased approximately 26%, or \$201,000, over the same period in 2002 from \$780,500 to \$981,500. This increase was the result of continued time and resources devoted to the development and testing of our emerging pesticide and silver ion technology product lines. Of the loss in the current period, \$1,204,000 is attributable to non-cash items: \$635,400 of non-cash start-up cost attributed to 651,000 warrants valued at \$0.976 per warrant used to acquire a three-part cross marketing and licensing agreement described below in the Liquidity and Capital Recourses section, \$225,400 of services paid with stock and warrants, \$155,500 of amortization and \$187,700 of depreciation.

LIQUIDITY AND CAPITAL RESOURCES

From inception through the present, we have financed our operations primarily through our initial public offering in August of 1996 and by subsequent private placement stock sales. In addition, the Company had obtained short term financing through a \$500,000 line of credit. In September 2002 the Company renegotiated its line of credit and extended it until November 2003. The extension includes an increase from \$500,000 to \$600,000 at an interest rate of 1 1/2 % per month secured against the entire assets of the Company excluding the Axenohl patent. The terms of the line of credit required the Company to maintain current accounts receivable of a minimum of \$350,000. At the end of year, the Company was in technical violation with this provision. The Company has neither requested nor received a waiver of this provision. The Company believes that this violation has no implications because the Company intends to pay off this line of credit with the sale of the trust deed and water treatment division as discussed below. In July 2003, the Company issued a \$300,000 convertible debenture at an interest rate of 10% per annum due July 2004.

The Company is currently attempting to strengthen its liquidity position by working with an investment banker because the Company requires an outside source of capital to fund planned projects relating to new product development and related product launches, research and development projects, regulatory approvals. The Company's operations alone may not generate cash flows, within

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

the next twelve months, sufficient to fund planned expansion.

In August of 2003, the Company completed a financing arrangement which included the acquisition of a \$1,600,000 Trust Deed asset in exchange for the issuance of 2,000,000 shares of the Company's common stock to a party unrelated to the grantor. In October 2003, the Company signed a term sheet to sell the Trust Deed asset for cash at face value. The purchasing party is also acquiring the water treatment division for \$2,750,000 in cash plus up to \$1,250,000 in deferred payments over the next year. Completion of the divestment of the water treatment division is subject to approval by PURE Bioscience shareholders. The Company intends to use a portion of the proceeds of this transaction to satisfy outstanding debt. The remaining proceeds should be sufficient to sustain operations and fund product development and commercialization until our bioscience technologies result in positive cash flow.

Although the Company has no plans to continue to fund operations with additional private placements of stock, we may evaluate opportunities to sell additional equity or debt securities, or obtain credit facilities from lenders to strengthen our financial position. The sale of additional equity or convertible debt securities could result in additional dilution to our stockholders.

Our liquidity is unaffected by the financing program offered to participating dealers in the Nutripure water dealer program. We receive funds from our lender and disperse the funds to the dealer, less a commission charged by us, upon completion of the contract. The lender disperses funds to us. We record a liability when the funds are received and relief of liability when funds are dispersed, and we do not retain liability on the credit extended.

July 31, 2003, our current assets to liabilities ratio decreased from 1.07 to 0.35. Current assets decreased \$590,200 from \$1,299,800 at July 31, 2002 to \$709,600 at July 31 2003 due to a decrease in inventories associated with lower sales volume and a large decrease in officer and employee loans and prepaid expenses. Current liabilities increased \$800,300 from \$1,120,000 to \$2,010,300. This increase was due mainly to an increase in loans from shareholders of \$100,000, the addition of a convertible debenture of \$180,500 and an increase in accounts payable of approximately \$488,100.

Net fixed assets decreased approximately \$181,200 due mainly to depreciation of equipment. Noncurrent assets decreased approximately \$151,100 due to amortization. Non-current assets of \$2,484,600 consist almost entirely of Patents and Licenses.

Cash flows used from operations were \$851,600 in the year ended July 31, 2003 and \$1,035,300 in 2002. For fiscal 2003, cash flows used in investing activities included \$500 for the purchase of machinery and equipment and \$4,300 for the purchase of patents and licenses. In fiscal 2002 cash flows used in investing activities included \$71,500 for the purchase of machinery and equipment and \$165,200 for the purchase of patents and licenses.

Cash flows from financing activities were \$956,300 in fiscal 2003 and \$1,216,200 in fiscal 2002. Financing activities for the current period included the addition of \$100,000 in loans from shareholders from a line of credit renegotiated in September 2002 and \$300,000 from a convertible debenture issued in July of 2003. Cash flows from financing activities also included an increase of common stock of \$556,325. During the current year, the Company conducted a \$250,000 private placement in which the Company issued 933,332 shares of common stock to six accredited investors at a price of \$0.30 per share (less costs), a \$200,000 private placement in which the Company issued 400,000 shares of common stock to six accredited investors at a price of \$0.50 per share and a \$60,000 private placement in which the Company issued 120,000 shares of common stock to three accredited investors at a price of \$0.50 per share. The Company also received \$81,325 from the exercise of options. In the prior period, cash flows

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

from financing activities included the addition of \$500,000 in notes payable from a line of credit established in September 2001. Cash flows from financing activities in the prior period also included an increase of common stock of \$435,300 which included a \$400,000 private placement in which the Company issued 250,000 shares of common stock to eleven accredited investors at a price of \$1.60 per share. The Company also received approximately \$68,000 from the exercise of options.

11

VALUATION OF INTANGIBLE ASSETS

SFAS 142 requires that goodwill and other intangible assets be tested for impairment on an annual basis and between annual tests in certain circumstances. Recoverability of assets to be held for use is based on expectations of future discounted cash flows from the related operations, and when circumstances dictate, the Company adjusts the asset to the extent the carrying value exceeds the fair value of the asset. Our impairment review process is based on the discounted future cash flow approach that uses our estimates of revenue driven by assumed market segment share and estimated costs. Also included in our analysis is an estimate of revenues expected from our agreement with Therapeutics, Inc. We have entered into an agreement with Therapeutics Inc. for the development and commercialization of FDA regulated Axenohl based products where Therapeutics is responsible for funding and directing all development activities and regulatory filings. In the agreement Therapeutics Inc. has agreed to reimburse the Company for \$2.2M of pre-contract acquisition and development costs of the Axenohl intellectual property as well as reimbursement for ongoing intellectual property costs associated with Axenohl. Following reimbursement of costs, depending on the type of product, the Company will receive 40% to 90% of all sales proceeds, licensing fees, royalty payments and all other forms of cash and non-cash consideration. The Company will also realize revenues from the sale of Axenohl raw material as an active ingredient.

Judgments made by the Company related to the expected useful lives of long-lived assets and the Company's ability to realize discounted cash flows in excess of the carrying amounts of such assets are affected by factors such as the ongoing maintenance and improvements of the assets and changes in economic and market conditions. As the Company assesses the ongoing expected cash flows and carrying amounts of our long-lived assets, these factors could cause the Company to realize a material impairment charge, which would result in decreased results of operations, and potentially decrease the carrying value of these assets.

Commitments

As a condition of the purchase agreement of the Axenohl patent, the Company agreed to make certain royalty payments to NVID of 5% of the gross product sales with a minimum royalty payment total of \$1,000,000 for the period from November 15, 2001 to July 31, 2004 and subsequently \$1,000,000 per year for the remaining life of the patent. The contract states that at July 31, 2004 the Company shall have the right, in its sole and absolute discretion, to do one of the following: a) pay the initial minimum royalty payment of \$1,000,000 in cash or common stock of the Company to NVID, less royalty amounts already paid, on or before July 31, 2004, b) transfer the patent back to NVID, at which time the Company would be released of any future minimum payments and granted a license to manufacture and distribute products covered by the patent while retaining all Axen and Axenohl related patents filed by the Company, including retention of all of its previously granted license rights to sell, distribute and manufacture all Axenohl based products, or c) cancel any royalty obligation under the contract by selling, transferring or assigning its ownership of the primary patent to a third party and paying NVID a percentage of the gross proceeds of 10% or 5%,

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

depending on how near the date of the transfer is to July 31, 2004, while retaining all Axen and Axenohl related patents filed by the Company, including retention of all of its previously granted license rights to sell, distribute and manufacture all Axenohl based products. The Company has not recorded or accrued an amount for the minimum royalty payments in the financial statements because the Company has determined that it is unlikely to choose the option to pay the minimum royalty.

In January 2003, the Company signed a cross-marketing and licensing agreement with Nickel Ltd., a manufacturer and distributor of wet wipes in Europe to acquire two "Super Distribution Agreements" and establish a 50/50 joint venture between PURE Bioscience and Nickel, to be known as CARLINE AMERICA LTD(TM). In exchange, and as total consideration on the Company's part, the Company agreed to issue a warrant to Nickel Ltd. to purchase 651,000 shares of common stock for \$0.0001 per share valued at \$635,000. This amount was expensed as start-up costs in the second quarter of the year. No cash was expended to acquire these agreements. Because of Nickel's failure to pay for product and failure to fulfill key material obligations under the contract, Company does not consider the warrant vested or exercisable and neither the warrant nor the common stock underlying the warrant will be issued.

12

PURE BIOSCIENCE

CONSOLIDATED FINANCIAL STATEMENTS

For the Years Ended July 31, 2003 and July 31, 2002

13

Independent Accountants' Report

Board of Directors
PURE Bioscience

We have audited the accompanying consolidated balance sheets for PURE

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

Bioscience as of July 31, 2003 and 2002, and the related consolidated statements of operations, statement of accumulated deficits and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with generally accepted auditing standards in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

The accompanying financial statements as of July 31, 2002 and for the year then ended have been restated to correct errors as described in Note 2.

In our opinion, the consolidated financial statements, referred to above, present fairly, in all material respects, the financial position of PURE Bioscience as of July 31, 2003 and July 31, 2002, and the results of its operations and its cash flows for the years then ended, in conformity with generally accepted accounting principles in the United States of America.

/s/ Miller and McCollom

MILLER AND MCCOLLOM, CPAs
4350 Wadsworth Boulevard, Suite 300
Wheat Ridge, Colorado
October 21, 2003

14

CONSOLIDATED BALANCE SHEETS

	July 31 2003	July 31 2002 (Restated) (See Note 2)
	-----	-----
ASSETS		
Current Assets		
Cash and cash equivalents	\$ 251,087	\$ 151,257
Accounts receivable, net of allowance for doubtful accounts of \$ 63,500 at July 31, 2003 and \$111,000 at July 31, 2002	163,895	166,601
Due from officers and employees	61	209,437
Inventories	287,940	595,071
Prepaid expenses	6,654	177,445
	-----	-----
Total current assets	709,637	1,299,811
	-----	-----
Property, Plant and Equipment		
Property, plant and equipment	432,744	613,909
	-----	-----

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

Total property, plant and equipment	432,744	613,909
	-----	-----
Noncurrent Assets		
Deposits	9,341	8,954
Patents and licenses	2,475,280	2,626,376
	-----	-----
Total noncurrent assets	2,484,621	2,635,330
	-----	-----
Total assets	\$ 3,627,002	\$ 4,549,050
	=====	=====
LIABILITIES AND STOCKHOLDERS EQUITY		
Current Liabilities		
Accounts payable	\$ 1,079,128	\$ 591,031
Accrued liabilities	150,688	118,975
Notes payable	180,513	-
Loans from shareholders	600,000	500,000
	-----	-----
Total current liabilities	2,010,329	1,210,006
	-----	-----
Stockholders' Equity		
Class A common stock, no par value: authorized		
50,000,000 shares, issued and outstanding		
10,594,088 at July 31, 2003 and		
8,400,899 at July 31, 2002	14,758,203	13,976,448
Warrants: issued and outstanding 1,037,429		
warrants	788,473	8,610
Accumulated deficit	(13,930,003)	(10,646,014)
	-----	-----
Total stockholders' equity	1,616,673	3,339,044
	-----	-----
Total liabilities and stockholders' equity	\$ 3,627,002	\$ 4,549,050
	=====	=====

The accompanying notes are an integral part of these financial statements

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Year Ended
July 31

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

	2003	2002 (Restated) (See Note 2)
Net revenues	\$ 2,589,496	\$ 3,206,44
Cost of sales	1,533,970	1,598,55
Gross profit	1,055,526	1,607,89
Selling expenses	466,198	749,34
General and administrative expenses	2,182,097	2,027,87
Research and development	981,493	780,51
Start-up costs	635,376	47,83
Total operating costs	4,265,164	3,605,56
Loss from operations	(3,209,638)	(1,997,66)
Other income and (expense):		
Interest income	1,333	9,99
Interest expense	(98,765)	(39,02)
Other	23,081	(2,40)
Total other income (expense)	(74,351)	(31,42)
Loss from continuing operations	(3,283,989)	(2,029,09)
Discontinued operations:		
Loss from discontinued operations	-	152,40
Loss from disposal of discontinued operations	-	41,04
Total discontinued operations	-	193,45
Net loss	\$ (3,283,989)	\$ (2,222,54)
Net loss per common share, basic and diluted		
Continuing operations	\$ (0.36)	\$ (0.2
Discontinued operations	-	(0.0
Net loss	\$ (0.36)	\$ (0.2

The accompanying notes are an integral part of these financial statements

CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the Year End July 31	
	2003	2002
		(Restated)
		(See Note 1)
Cash flows from operating activities		
Net loss	\$ (3,283,989)	\$ (2,221,000)
Adjustments to reconcile net income to net cash provided by operating activities:		
Amortization	155,461	18,000
Depreciation	181,697	26,000
Services paid for with stock and warrants	885,509	10,000
Changes in assets and liabilities:		
(Increase) decrease in accounts receivable	2,706	40,000
(Increase) decrease in due from officers and employees	209,376	3,000
(Increase) decrease in prepaid expense	171,087	1,000
(Increase) decrease in inventory	307,131	11,000
(Increase) decrease in deposits	(387)	
Increase (decrease) in accounts payable	488,097	4,000
Increase (decrease) in accrued liabilities	31,713	2,000
Net cash provided (used) by operating activities	(851,599)	(1,031,000)
Cash flows from investing activities		
Purchase of patents and licenses	(4,365)	(7,000)
Purchase of property, plant and equipment	(531)	(16,000)
Net cash (used) in investing activities	(4,896)	(23,000)
Cash flows from financing activities		
Proceeds from debt obligations	400,000	50,000
Proceeds from sale of common stock	556,325	71,000
Net cash provided by financing activities	956,325	1,21,000
Net increase (decrease) in cash and cash equivalents	99,830	(5,000)
Cash and cash equivalents at beginning of period	151,257	20,000
Cash and cash equivalents at end of period	\$ 251,087	\$ 15,000

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

Supplemental disclosures of cash flow information

Cash paid for interest paid	\$	98,765	\$	3
Cash paid for taxes paid	\$	3,500	\$	
Noncash investing and financing activities:				
Value of shares issued in exchange for Silver Ion Technology patent			\$	1,54

The accompanying notes are an integral part of these financial statements

PURE Bioscience Notes to Consolidated Financial Statements See Independent Accountants' Report

Note 1. Organization and Summary of Significant Accounting Policies

This summary of significant accounting policies of PURE Bioscience (formerly Innovative Medical Services) is presented to assist in understanding the Company's financial statements. The financial statements and notes are representations of the Company's management who is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles in the United States of America and have been consistently applied in the preparation of the financial statements. The financial statements are stated in United States of America dollars.

Organization and Business Activity The Company was incorporated as Innovative Medical Services in San Diego, California on August 24, 1992 as a provider of pharmaceutical water purification products. Based on revenues, the Company's primary business is the sale and manufacture of residential and commercial water filtration systems. In addition, the Company produces, manufactures and licenses silver ion bioscience technologies (Axenohl and Axen) and produces products for the pesticide industry (Innovex). In September 2003 the Company effected a name change as approved by shareholders to PURE Bioscience.

In October of 1998, the Company formed a subsidiary, EXCOA Nevada to purchase the assets of Export Company of America, Inc. (EXCOA), a privately held Fort Lauderdale, Florida-based distributor of disposable medical, dental and veterinary supplies. The major asset of this company was its 45% interest in Ampromed Comercio Importacao E Exportacao Ltda (AMPROMED), a Rio de Janeiro-based import company that sells medical, dental and veterinary supplies and water filtration products to practitioners, retail outlets and government agencies. The Company acquired the remaining 55% interest in AMPROMED from a private individual and transferred it to EXCOA Nevada.

In November 2000, PURE Bioscience acquired 100% of the stock of ETIH2O, Inc, a privately held technology corporation that developed Axenohl and is responsible for processing, and production of Axenohl and Axen. ETI-H2O is also responsible for all supervision of all research, studies, data and quality control of the Axenohl/Axen product line.

Basis of Presentation and Principles of Consolidation

The accompanying financial statements include the consolidated accounts of PURE Bioscience and its subsidiaries. All inter-company balances and transactions

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

have been eliminated.

Revenue Recognition

Generally, the company recognizes income based upon concluded arrangements with customers and when all events have occurred by delivery or performance. Certain income is recognized upon shipment where the sale is made f.o.b. shipping point including sales to dealers and pharmacies. Customer acceptance provisions and installation procedures accompanying delivery are minor in nature, and the Company has not experienced any material expense in satisfying warranties and returns.

The Company has a program of providing financing to independent dealers for equipment of other manufacturers and not the Company's products. The Company receives funds from its primary lender and disperses the funds to the dealer, less a commission charged by the Company, upon completion of the contract. The Company records the commissions earned as revenues when received.

Most of the Company's chain customers have entered into multi-year contracts for the Customer Service Plan 2000. The CSP 2000 provides an extended warranty on PURE Bioscience's Fillmaster pharmacy products; significant discounts on maintenance item costs; free software upgrades for the Fillmaster 1000e and Scanmaster; automatic replacement filter shipments; and simplified, annual invoicing. When the customer buys a dispenser on the Customer Service Plan 2000 it agrees to pay a fixed annual fee that covers replacement filters and parts. The filters should be replaced once a year. In order to match income with related costs, and for simplicity in accounting and billing, the Company bills the customer the annual fee and recognizes the revenue in the same month that it ships the replacement filters to the store. This is done one year after the store is added to the Plan and each year thereafter. Future warranty costs associated with the CSP 2000 Plan are discussed in Note 18.

Accounts Receivable

The Company sells on terms of cash or net 30 days. Invoices not paid within stated terms are considered delinquent. The Company analyzes its accounts receivable periodically and recognizes an allowance for doubtful accounts based on estimated collectibility. Individual accounts deemed uncollectible are charged to the allowance. At July 31, 2003, \$47,500 was considered past due, determined by 90 day after invoice date.

Stock-Based Compensation

The Company follows FASB Statement No. 123, 'Accounting for Stock-Based Compensation' ('FAS 123'). The provisions of FAS 123 allow companies to either expense the estimated fair value of stock options or to continue to follow the intrinsic value method set forth in APB Opinion 25, 'Accounting for Stock Issued to Employees' ('APB 25') but disclose the pro forma effects on net income (loss) had the fair value of the options been expensed. The Company has elected to continue to apply APB 25 in accounting for its stock option plans. For awards that generate compensation expense as defined under APB 25, the Company calculates the amount of expenses and recognizes the expense over the vesting period of the award.

In March 2000, the FASB issued FASB Interpretation No. 44, 'Accounting for Certain Transactions Involving Stock Compensation' ('FIN 44'), which contains rules designed to clarify the application of APB 25. FIN 44 became effective on July 1, 2000 at which time the Company adopted it. The impact of the adoption of FIN 44 was not material to the earnings or financial position of the Company.

Research and Development

Research and Development costs that have no alternative future uses are charged

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

to operations when incurred and are included in operating expenses. The total amount charged to Research and Development expense was \$981,500 and \$780,500 in the fiscal years ended July 31, 2003 and 2002, respectively.

Depreciation Method

The cost of property, plant and equipment is depreciated on a straight-line basis over the estimated useful lives of the related assets. The useful lives of property, plant, and equipment for purposes of computing depreciation are:

Computers and equipment	7.0 years
Furniture and fixtures	10.0 years
Website	3.0 years
Vehicle	5.0 years to 7.0 years

Leasehold improvements are being depreciated over the life of the lease, which is equal to 120 months.

Amortization of Intangible Assets

The cost of patents acquired is amortized on a straight-line basis over the remaining lives of the patents. Licenses are amortized on a straight-line basis over periods ranging from 15 to 20 years. The weighted average amortization period for all patents and licenses is 17.56 years. The estimated amortization expense over each of the next five years is \$155,700.

Amortization expense for the years ended July 31, 2003 and July 31, 2002 was \$155,500 and \$187,900, respectively.

Long-Lived Assets

In accordance with Financial Accounting Standards Board ("FASB") Statement of Financial Accounting Standards ("SFAS") No. 121, Accounting for Impairment of Long-Lived Assets, and for Long-Lived Assets to be Disposed, the Company periodically analyzes its intangible assets and long-lived assets for potential impairment, assessing the appropriateness of lives and recoverability of unamortized balances through measurement of undiscounted operation cash flows on a basis consistent with accounting principles generally accepted in the United States of America.

Inventory

Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories at July 31 consisted of:

	2003	2002
	-----	-----
Finished Goods	\$ 133,900	\$ 257,600
Work in Progress	0	29,900
Raw Materials	181,900	334,600
	-----	-----
	\$ 315,800	\$ 622,100
	-----	-----

Use of Estimates

The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

Fair Value of Financial Instruments

The carrying amounts for cash equivalents, receivables, and payables approximate fair value because of the short maturity, generally less than three months, of these instruments. The carrying value of the Company's line of credit approximates fair value since the current borrowing rates available for financing are similar in terms.

Advertising and Promotional Costs

Cost of advertising and promotion are expensed as incurred. Such costs were \$466,200 and \$448,800 for the years ended July 31, 2003 and July 31, 2002, respectively.

Net Income (Loss) Per Common Share

The Company adopted FASB Statement No. 128, Earnings Per Share ("SFAS 128"), which is effective for periods ending after December 15, 1997. Entities that have only common stock outstanding are required to present basic earnings per share amounts. All other entities are required to present basic and diluted per share amounts. Diluted per share amounts assume the conversion, exercise or issuance of all potential common stock instruments unless the effect is to reduce a loss or increase the income per common share from continuing operations.

Following is a reconciliation of the weighted average number of shares actually outstanding with the number of shares used in the computations of loss per common share:

	For the Years Ended July 31, 2003	July 31, 2002
	-----	-----
Shares outstanding	10,594,088	8,400,000
Weighted average number of shares actually outstanding	9,153,887	7,600,000
Stock Options	4,144,375	3,500,000
Warrants	1,037,429	-----
Total weighted average shares	14,335,691	11,000,000
Loss from continuing operations	\$ (3,174,259)	\$ (2,200,000)
Loss from discontinued operations	-	(100,000)
Net loss	\$ (3,174,259)	\$ (2,300,000)
Net loss per common share		
Continued operations	\$ (0.35)	\$ (0.30)
Discontinued operations	(0.00)	-----
Net loss	\$ (0.35)	\$ (0.30)
	=====	=====

Income Taxes

The Company records deferred taxes in accordance with Statement of Financial

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

Accounting Standards (SFAS) No. 109, "Accounting for Income Taxes." The statement requires recognition of deferred tax assets and liabilities for temporary differences between the tax bases of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.

Other

The Company's fiscal year end is July 31.

The Company paid no cash dividends during the periods presented.

Shipping and handling costs payable by the Company are charged to cost of sales.

Certain comparative figures have been reclassified to conform to the current year presentation.

All of the Company's assets are located in the United States.

Note 2. Restatement of Financial Statements - Start-up Costs and Warranty Liability

The accompanying financial statements have been restated to correct an error in the recording and reporting of Start-up Costs and the Warranty Liability of the Company.

The Company expended \$230,000 during the year ended July 31, 2001 and an additional \$47,831 during the July 31, 2002 fiscal year in an effort to acquire and set up a Korean corporation. The Company capitalized these costs as Deferred Acquisition costs as incurred. The Company later determined the venture was not feasible and decided not to go forward with the project. The total costs of \$277,831 were written-off as Abandoned Projects at July 31, 2002. We now believe the treatment of these costs was not correct. The accompanying financial statements now show these costs as expensed when incurred as Start-up Costs. The effect of this restatement was to increase the net loss at July 31, 2001 by \$230,000 and to decrease the net loss at July 31, 2002 by \$230,000.

In previous years the Company had not recorded a liability for its future warranty obligation. Because the Company has now computed and booked this liability the accompanying financial statements have been restated to include this obligation.. A liability of \$42,430 at July 31, 2003 and \$41,445 at July 31, 2002 are included in Accrued Liabilities. The income statement effect of these items was to reduce net loss at July 31, 2001 by \$729 and to increase net loss at July 31, 2002 by \$7,654.

The accompanying financial statements also include 15,000 warrants issued for \$8,310 that were omitted from the July 31, 2002 balance sheet in error.

Note 3. Cash and Cash Equivalents

For purposes of the balance sheets and statements of cash flows, the Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. At July 31, 2003, the Company had deposits of \$124,842 in excess of FDIC insured limits. At July 31, 2002, the Company had no deposits in excess of FDIC insured limits.

Note 4. Due from Officers and Employees (Related Parties)

At July 31, 2003, there were no amounts due from officers and \$61 represents amounts due from employees. At July 31, 2002, there were notes receivable of \$64,075 due from officers and \$145,362 due from employees. All notes receivable are due and payable within one year. The carrying value of the notes, based on the terms at which those same loans would be made currently, approximate their

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

fair value. All notes in excess of \$10,000 have interest accrued at 6%. Advances to employees of amounts under \$10,000 are not charged interest. The total of these loans to employees of under \$10,000 was \$61 at July 31, 2002 and \$7,620 at July 31, 2002.

Note 5. Property, Plant and Equipment

The following is a summary of property, plant, and equipment - at cost, less accumulated depreciation:

	July 31, 2003	July 31, 2002
	-----	-----
Computers and equipment	\$ 1,081,046	\$ 1,076,466
Furniture and fixtures	108,129	103,855
Website	-	207,916
Vehicle	50,985	50,985
Leasehold improvements	309,830	307,606
	-----	-----
	1,549,990	1,746,828
Less: accumulated depreciation and amortization	1,117,246	1,091,870
	-----	-----
Total	\$ 432,744	\$ 654,958
	-----	-----

Depreciation expense charged to general and administrative expense for the years ended July 31, 2003 and July 31, 2002 was \$320,500 and \$266,500, respectively.

Note 6. Notes Payable

The details relating to note payable are as follows:

	July 31, 2003	July 31, 2002
	-----	-----
Convertible Debenture, interest payable quarterly at 10% per annum due and payable on July 24, 2004.	\$ 300,000	\$ -
Discount	(119,487)	-
Current maturities of notes payable included in current liabilities	180,513	-
	-----	-----
Total long term debt	\$ -	\$ -
	-----	-----

The note contains a provision that the holder can demand the note be paid in full in cash if the Company obtains any future financing (whether debt or equity) of at least \$500,000. If held to maturity, principal is automatically converted to common shares of the Company at the conversion price of \$0.50 per

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

share. The conversion price can be reset after 180 days and again after one year to 75% of the trading price of the stock if the per share price falls below \$0.75 on those dates. The note was contained in a Unit Purchase Agreement in which the holder of the note receives 300,000 five-year warrants to purchase common stock of the Company at an exercise price of \$0.75. The recorded value of the note payable and the warrants were apportioned based on their respective fair values. This resulted in the note being recorded at its discounted value of \$180,513. The discount of \$119,487 will be amortized over the one-year life of the note. If the contract were to have settled on July 31, 2003, the Company would have had to pay the holder of the note 600,000 shares of common stock. The maximum amount of shares the Company would be required to pay under the contract is the lower of 75% of the price of the Company's common stock at the 180 day or one-year reset dates divided by the \$300,000 face value of the note.

Note 7. Loans from Shareholder

The details relating to loans from shareholders are as follows:

	July 31, 2003	Ju
	-----	--
Line of Credit (from shareholder) \$600,000 line of credit, interest at 18% Due and payable November 13, 2003		
Secured by total assets of the Company	\$ 600,000	\$
Excluding the Axenohl patent		
Current maturities of loans payable included in current liabilities	600,000	

Total long term debt	\$ -	\$
	-----	--

The terms of the line of credit required the Company to maintain current accounts receivable of a minimum of \$350,000. At the end of year, the Company was in technical violation with this provision. The Company has neither requested nor received a waiver of this provision.

Note 8. Warranty Liability

In November 2002, the FASB issued Interpretation No. 45, "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others". Interpretation 45 is effective for financial statements of interim or annual periods fiscal years ending after December 15, 2002 and requires the following disclosures of the Company's product warranties:

The Company provides a standard warranty of two years for replacement parts on all Fillmaster systems sold. Most of the Company's chain customers have entered into multi-year contracts for the Customer Service Plan 2000. The CSP 2000 provides an extended unlimited warranty on all PURE Bioscience pharmacy products; significant discounts on maintenance item costs; free software upgrades for the Fillmaster 1000e and Scanmaster; automatic replacement filter shipments; and simplified, annual invoicing. When the customer buys a dispenser on the Customer Service Plan 2000 it agrees to pay a fixed annual fee that covers replacement filters and parts. The Company monitors the costs of providing replacement parts other than filters.

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

This cost has remained steady and is computed as a percentage of related revenues. The following is a summary of changes in the Company's product warranty liability.

	Beginning Liability -----	Expense Incurred -----	Warranty Payments -----
Year ended July 31, 2002	\$ 33,791 =====	\$ 39,602 =====	\$ 31,948 =====
Year ended July 31, 2003	\$ 41,445 =====	\$ 33,692 =====	\$ 32,707 =====

Note 9. Commitments

On May 14, 1996, the Company entered into an operating lease agreement for its home office which expires (under extension) in October 2006. The lease includes a yearly increase of 4%. The rental expense recorded in general and administrative expenses for the years ended July 31, 2003 and July 31, 2002 was \$160,545 and \$144,348, respectively. Future minimum rental payments required for each of the 5 succeeding years assuming exercise of the option are as follows:

Year Ended July 31 -----	Amount -----
2004	\$166,967
2005	\$173,645
2006	\$180,591
2007	\$187,815
2008	\$195,328

The Company has an employment contract with its Chief Executive Officer/President which includes a provision for him to be paid an amount equal to 3% of the Company's net income before taxes, if any.

On November 30, 2001 the Company acquired the patent for Axenohl, a silver ion based technology (Note 17). As a condition of the purchase agreement of the Axenohl patent, the Company agreed to make certain royalty payments to NVID of 5% of the gross product sales with a minimum royalty payment total of \$1,000,000 for the period from November 15, 2001 to July 31, 2004 and subsequently \$1,000,000 per year for the remaining life of the patent. The contract states that at July 31, 2004 the Company shall have the right, in its sole and absolute discretion, to do one of the following: a) pay the initial minimum royalty payment of \$1,000,000 in cash or common stock of the Company to NVID, less royalty amounts already paid, on or before July 31, 2004, b) transfer the patent back to NVID, at which time the Company would be released of any future minimum payments and granted a license to manufacture and distribute products covered by the patent while retaining all Axen and Axenohl related patents filed by the Company, including retention of all of its previously granted license rights to sell, distribute and manufacture all Axenohl based products, or c) cancel any royalty obligation under the contract by selling, transferring or assigning its ownership of the primary patent to a third party and paying NVID a percentage of the gross proceeds of 10% or 5%, depending on how near the date of the transfer is to July 31, 2004, while retaining all Axen and Axenohl related patents filed by the Company, including retention of all of its previously granted license

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

rights to sell, distribute and manufacture all Axenohl based products. The Company has not recorded or accrued an amount for the minimum royalty payments in the financial statements because the Company has determined that it is unlikely to choose the option to pay the minimum royalty. There are potential minimum royalties due of \$1,000,000 for the period of November 2001 to July 31, 2004 and for each fiscal year thereafter. Future minimum royalty payments required for each of the 5 succeeding years are as follows:

Year Ended July 31 -----	Amount -----
2004	\$1,000,000
2005	\$1,000,000
2006	\$1,000,000
2007	\$1,000,000
2008	\$1,000,000

The maximum royalty payments cannot be estimated because they are based on future sales.

In June 2003, the Company signed a Letter of Engagement with GunnAllen Financial to become the Company's exclusive financial advisor. In the agreement the Company agreed to pay GunnAllen Financial a fee of \$10,000 per month for a period of two years. As additional compensation, in August of 2003 the agreement was amended to include a warrant to purchase 200,000 shares of common stock of the Company at a strike price of \$0.80.

Note 10. Equity and Common Stock

The following schedule summarizes the change in equity:

	Common Stock Shares -----	Common Stock \$ -----	Warrants Issued -----	Warrants \$ -----	Accumul Defic -----
Balance, July 31, 2001	6,954,699	\$11,510,915	4,472,500	\$108,750	\$(8,423,000)
Sale of Stock	35,200	75,183			
Private Placement	511,000	641,000			
Shares Issued for Services	200,000	100,000			
Warrants Issued for Services			15,000	8,610	
Expiration of Warrants		108,750	(4,472,500)	(108,750)	
Purchase of Patents	700,000	1,540,600			
Net Loss	0	0	0	0	(2,222,000)
Balance, July 31, 2002	8,400,899	13,976,448	15,000	8,610	(10,646,000)
Sale of Stock	72,500	81,325			

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

Private Placement	1,788,439	475,000	371,429	144,487	
Shares Issued for Services	332,250	225,430			
Warrants Issued for Services			666,000	635,376	
Net Loss	0	0	0	0	(3,283,
	-----	-----	-----	-----	-----
Balance, July 31, 2003	10,594,088	\$14,758,203	1,037,429	\$ 788,473	\$(13,930,
	=====	=====	=====	=====	=====

The Company also has 5,000,000 shares of preferred stock authorized, no preferred stock has been issued.

The following schedule summarizes the outstanding warrants:

Issued For	Date Issued	Amount	\$ Amount	Weighted Average Exercise Price	Exercise Price	Expiration Date
-----	-----	-----	-----	-----	-----	-----
Services	6/14/02	15,000	\$8,610	\$1.00	\$1.00	6/14/03
Private Placement	1/31/03	71,429	25,000	\$0.30	\$0.30	1/31/04
Start-up Costs	1/15/03	651,000	635,376	\$0.001	\$0.001	1/15/04
Private Placement	7/24/03	300,000	119,487	\$0.75	\$0.75	7/24/04
Total		1,037,429	\$788,473			
		=====	=====			

The Company had issued Class A warrants which entitled the holder to acquire an additional common share for \$5.25 per common share beginning August 8, 1997 and expiring August 8, 2001. The Class A Warrants were redeemable by the Company for \$0.05 per warrant, at the Company's option, commencing one year after the effective date of the offering provided the closing bid price for the Company's common shares shall have averaged in excess of \$9.00 per share for thirty consecutive business days ending within five days of the date of notice of redemption.

The Company had issued Class Z warrants which entitled the holder to acquire an additional common share for \$10.00 per common share beginning August 8, 1998 and expiring August 8, 2001. The Class Z Warrants were redeemable by the Company for \$0.10 per warrant, at the Company's option, commencing one year after the

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

effective date of the offering provided the closing bid price for the Company's common shares shall have averaged in excess of \$15.00 per share for thirty consecutive business days ending within five days of the date of notice of redemption.

On August 8, 2001 the total 3,687,500 Class A warrants and the total 785,000 Class Z warrants expired without exercise.

Note 11. Related Party Transactions
See Note 7.

Note 12. Stock Option Plans

The Company has the following stock option plans (the Plans) pursuant to which options to acquire common stock have been granted.

1996 Incentive Stock Option Plan: Approved by Shareholders in April, 1996 with 1,000,000 shares authorized under this Plan. The options have a five-year term with vesting ratably over a five-year period.

1996 Directors and Officers Stock Option Plan: Adopted by the Board in April, 1996 with 1,000,000 shares authorized under this Plan. The maximum number of shares subject to options granted under this Plan to any one Director or Officer shall not exceed 200,000 shares in any 12-month period. The options have a five-year term with vesting ratably over a five-year period.

Amended 1998 Directors and Officers Stock Option Plan: Approved by Shareholders in December, 1998 with 2,000,000 shares authorized under this Plan. The maximum number of shares subject to options granted under this Plan to any one Director or Officer shall not exceed 200,000 shares in any 12-month period. The options have a five-year term with vesting ratably over a five-year period.

2001 Directors and Officers Stock Option Plan: Approved by Shareholders in January 2001 with 1,000,000 shares authorized under this Plan. The maximum number of shares subject to options granted under this Plan to any one Director or Officer shall not exceed 200,000 shares in any 12-month period. The options have a five-year term with vesting ratably over a five-year period.

2001 ETIH2O Stock Option Plan: Adopted by the Board in January 2001 with 1,000,000 shares authorized under this Plan. The options have a five-year term with vesting ratably over a five-year period.

2001 Consultants and Advisors Stock Option Plan: Adopted by the Board in January 2001 with 500,000 shares authorized under this Plan. The maximum number of shares subject to options granted under this Plan to any one participant shall not exceed 50,000 shares in any 12-month period. The options have a five-year term with vesting ratably over a five-year period.

On March 11, 2002, the Company's shareholders approved the PURE Bioscience 2002 Employee Incentive Stock Option Plan. The purpose of the Plan is to advance the business and development of the Company and its shareholders by affording to the key employees and non-employee directors of the Company the opportunity to acquire a propriety interest in the Company by the grant of Options to acquire shares of the Company's common stock.

The Options granted are "Incentive Stock Options" within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended, for certain key employees. The Plan is administered by an Administrative Committee whom shall serve a one-year term. Subject to anti-dilution provisions, the Plan may issue Options

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

to acquire up to 4,000,000 shares to Key Employees. The exercise price for Options shall be set by the Administrative Committee but shall not be for less than the fair market value of the shares on the date the Option is granted. The period in which Options can be exercised shall be set by the Administrative Committee not to exceed five years from the date of Grant. The Plan may be terminated, modified or amended by the Board of directors upon the recommendation of the Administrative Committee. The options vest ratably over a five-year period.

On March 11, 2002, the Company's shareholders approved the PURE Bioscience 2002-Non-Qualified Stock Option Plan. The purpose of the Plan is to advance the business and development of the Company and its shareholders by affording Eligible Plan Participants the opportunity to acquire a proprietary interest in the Company by the grant of Options to acquire shares of the Company's common stock. Eligible Plan Participants include the Directors and Officers of the Company, consultants, advisors and other individuals deemed by the Compensation Committee to provide valuable services to the Company but who are not otherwise eligible to participate in the Employee Incentive Stock Option Plan.

The Plan is administered by an Administrative Committee whom shall serve a one-year term. The Administrative Committee is composed of the Board's Compensation/Administration Committee. Subject to anti-dilution provisions, the Plan may issue Options to acquire up to 2,000,000 shares to Eligible Plan Participants. The Company will not receive any consideration for the grant of options under the Plan and approximate market value of the shares to be reserved for the plan is \$4,000,000 based upon the average thirty trading day closing price for the Company's common stock for the period ending January 31, 2002. The exercise price for Options shall be set by the Administrative Committee but shall not be for less than the fair market value of the shares on the date the Option is granted. Fair market value shall mean the average of the closing price for ten consecutive trading days at which the Stock is listed in the Nasdaq quotation system ending on the day prior to the date an Option is granted. The period in which Options can be exercised shall be set by the Administrative Committee not to exceed five years from the date of Grant.

The Company estimates a fair value method of accounting for stock-based compensation in accordance with Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation" (SFAS 123). In accordance with SFAS 123, the Company has chosen to continue to account for employee stock-based compensation utilizing the intrinsic value method. Accordingly, compensation cost for stock options is measured as the excess, if any, of the fair market price of the Company's stock at the date of grant over the amount an employee must pay to acquire the stock.

Also, in accordance with SFAS 123, the Company has provided footnote disclosure with respect to stock-based employee compensation. The cost of stock-based employee compensation is measured at the grant date based on the value of the award and is recognized over the service period. The value of the stock based award is determined using a pricing model whereby compensation cost is the excess of the fair value of the stock as determined by the model at grant date or other measurement date over the amount an employee must pay to acquire the stock.

The Company accounts for non-employee stock based compensation by recording the fair value of the stock options granted over the anticipated service period.

The effect of applying FAS 123 on the years ended July 31, 2003 and 2002 pro forma net loss as stated below is not necessarily representative of the effects on reported net loss for future years due to, among other things, the vesting period of the stock options and the fair value of additional stock options in future years. Had compensation cost for the Company's stock option plans been determined based upon the fair value at the grant date for awards under the

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

plans consistent with the methodology prescribed under FAS 123, the Company's net loss in the years ended July 31, 2003 and 2002 would have been approximately \$4,014,900 and \$2,856,400 or \$(0.44) per share and \$(0.38) per share, respectively, on a diluted basis. Compensation cost for non-employees of \$191,600 was charged to income in the year ended July 31, 2003 and \$27,300 in the year ended July 31, 2002. The weighted average fair value of the options

granted during the years ended July 31, 2003 and 2002 are estimated at \$1.16 per share and \$1.13 per share, respectively, on the date of grant using the Black-Scholes option-pricing model. The following assumptions were used for grants in 2003 and 2002; no dividend yield, volatility of 137.78% and 101.48%, respectively; a risk-free interest rate of 2.25% and 5.25%, respectively and an expected life of 2.24 and 2.98 years from date awarded.

A summary of stock option activity is as follows:

	Number of Shares	Weighted-Average Exercise Price (\$)
Balance at July 31, 2001	2,734,966	1.72
Granted	1,850,000	1.56
Exercised	(35,200)	1.93
Forfeited	(338,091)	1.63

Balance at July 31, 2002	4,211,675	1.74
Granted	637,500	0.50
Exercised	(156,875)	0.55
Forfeited	(0)	0.00

Balance at July 31, 2003	4,692,300	1.64
	=====	

Range of Exercise Prices	Number Shares Outstanding	Outstanding		Number Exercised
		Weighted Average Remaining Life (in years)	Weighted Average Exercise Price	
-----		-----	-----	-----
\$0.50 to \$0.74	1,125,000	3.30	\$0.53	89
\$1.00	523,750	0.70	\$1.00	51
\$1.31 to \$1.90	547,300	3.70	\$1.72	53
\$2.00	1,600,000	2.25	\$2.00	1,30
\$2.10 to \$2.50	460,000	3.18	\$2.11	46
\$2.93 to \$3.56	436,250	1.31	\$3.05	43
	-----			-----
	4,692,300	2.24	\$1.61	4,14
	=====			=====

Note 13. Pension Plan

The Company participates in a Small SEP program under which the employer makes

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

contributions to a SEP, which includes a salary reduction arrangement (SARSEP). Employees who participate in the SARSEP may elect to have the employer: (a) make contributions to the SEP on their behalf, or (b) pay them cash. A salary reduction arrangement may be used only in years in which the SEP meets requirements that the IRS may impose to ensure distribution of excess contributions. Annual contributions of an employer under a SEP are excluded from the participant's gross income. No employer contributions were made during the fiscal years ending July 31, 2003 and July 31, 2002.

Note 14. Income Taxes

The current provisions for income taxes of \$3,200 for fiscal year ended July 31, 2003 and \$2,400 for July 31, 2002 is the minimum franchise tax paid to the State of California regardless of income or loss. The Company files federal and California consolidated tax returns with its subsidiaries.

At July 31, 2003, the Company had federal, and California tax net operating loss carryforwards of approximately \$12,030,000 and \$4,945,700 respectively. At July 31, 2001, the Company had federal, and California tax net operating loss carryforwards of approximately \$9,796,900 and \$3,717,500 respectively. The difference between the financial reporting and the federal tax loss carryforwards is primarily due to accrued expenses and valuation allowances reported in the financials but not deductible for tax purposes. The difference between federal and California tax loss carryforwards is primarily due to the limitation on California loss carryforwards. The federal tax loss carryforwards will begin expiring in the fiscal year ended July 31, 2011, unless previously utilized and will completely expire in fiscal year ended July 31, 2023. The California tax loss carryforwards will begin to expiring in fiscal year ended July 31, 2011, unless previously utilized and will completely expire in fiscal year ended July 31, 2023.

The Company has total deferred tax assets of approximately \$4,726,000 and \$3,325,700 for the fiscal years ended July 31, 2003 and 2002, respectively. Realization of these deferred tax assets, which relate to operating loss carryforwards and timing differences, is dependant on future earnings. The timing and amount of future earnings are uncertain and therefore, the valuation allowance had been established. The increase in the valuation allowance on the deferred tax asset during the fiscal year ended July 31, 2003 was \$950,300.

Significant components of the Company's deferred tax assets are as follows:

	July 31, 2003

Net operating loss carryforward	\$ 4,551,000
Depreciation and amortization	124,600
Calculation allowances	(292,800)
Stock options and warrant	385,400
Other	(42,200)

Total deferred tax assets	4,726,000
Valuation allowance for deferred tax assets	(4,276,000)

Net deferred tax assets	\$ 0
	=====

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

A reconciliation of income taxes computed using the statutory income tax compared to the effective tax rate is as follows:

	2003

Federal tax benefit at the expected statutory rate	34 %
State income tax, net of federal tax benefit	9
Valuation allowance	(43)

Income tax benefit - effective rate	0 %
	=====

Note 15. Risks and Uncertainties

The Company faces competitive risks for its Axenohl and pesticide products because the products displace traditional technologies sold by better capitalized and established companies.

A significant part of the Company's revenues are from pharmaceutical water products.

Note 16. Business Segment and Sales Concentrations

In accordance with the provisions of SFAS No. 131, certain information is disclosed based on the way management organizes financial information for making operating decisions and assessing performance. In determining operating segments, the Company reviewed the current management structure reporting to the chief operating decision-maker ('CODM') and analyzed the reporting the CODM receives to allocate resources and measure performance.

The Company's business activities are divided, managed and conducted in two basic business segments, the Water Treatment segment and the Bioscience segment. These two segments were determined by management based upon the inherent differences in the end use of the products, the inherent differences in the value added processes made by the Company, the differences in the regulatory requirements and the inherent differences in the strategies required to successfully market finished products. The Water Treatment segment includes Commercial Water and Residential Retail products and the Nutripure Water Dealer program. Bioscience includes Axenohl (Silver Ion Technology) and the Innovex line of pest control products.

Segment information is presented in accordance with SFAS 131, Disclosures about Segments of an Enterprise and Related Information. This standard is based on a management approach, which requires segmentation based upon the Company's internal organization and disclosure of revenue and operating income based upon internal accounting methods. The Company's financial reporting systems present various data for management to run the business, including internal profit and loss statements prepared on a basis not consistent with U.S. generally accepted accounting principles. Reconciling amounts consist of unallocated general and administrative expenses.

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

	Water Treatment	Biosciences	Reconc Amou
2003			
Revenues			
Commercial Water Treatment			
Fillmaster Products	\$1,160,700		
Replacement Filters (Includes CSP 2000)	640,600		
Residential Water Treatment	155,200		
Water Dealer Program	517,300		
Silver Ionization	-	\$ 54,500	
Pesticide	-	61,200	
Total Revenues	\$2,473,800	\$ 115,700	\$
Operating Income/(Loss)	\$ 379,900	\$ (173,083)	\$ (2,967,
Segment Assets	\$ 423,300	\$2,436,100	
2002			
Revenues			
Commercial Water Treatment			
Fillmaster Products	\$1,161,800		
Replacement Filters (Includes CSP 2000)	524,000		
Residential Water Treatment	106,400		
Water Dealer Program	396,700		
Silver Ionization	-	\$ 683,100	
Pesticide	-	334,400	
Total Revenues	\$ 2,188,900	\$ 1,017,500	\$
Operating Income/(Loss)	\$ 186,100	\$ (717,300)	\$ (1,691,
Segment Assets	\$ 790,200	\$ 2,450,100	

Significant customers primarily consisted of domestic retail chain pharmacies. Sales concentrations to major chain stores were approximately \$923,000 and export sales were \$73,000 for the year ended July 31, 2003. Sales concentrations to major chain stores were approximately \$1,107,200 and export sales were \$584,600 for the year ended July 31, 2002. No customer accounted for more than 10% of consolidated sales.

Note 17. Patent Acquisition

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

On November 30, 2001, the Company acquired the patent for Axenohl, a silver ion based technology which is the basis for the Company's silver ion products. The Company previously licensed the use of this patent.

The Company purchased the patent for 700,000 shares of its common stock plus certain expenses. The Company valued the patent at \$1,540,600 based on the market price of the stock exchanged. In addition, the Company agreed to pay royalties in the amount of 5% of gross Axenohl sales until March 2018, the end of the life of the patent including minimum royalties (see Note 9).

Note 18. Discontinued Operations

In December 1999, the Company formed NUTRIPURE.COM as a wholly owned subsidiary to operate an e-commerce health website, composed primarily of Bergen Brunswig products. On January 15, 2002, Bergen Brunswig Corporation terminated the distribution license for these products. As a result, we closed our e-commerce division. The Nutripure subsidiary now is holding the website for resale, which is its only remaining asset. Assets of the subsidiary were zero at July 31, 2003 and zero at July 31, 2002. Revenues from discontinued operations were zero in 2003 and \$1,000 in 2002. No income tax expense was allocated to discontinued operations because of the uncertainty of realizing net operating loss carryforwards.

Note 19. Subsequent Events

In August of 2003 the Company completed a financing arrangement which included the acquisition of a \$2,000,000 Trust Deed receivable and \$35,000 related accrued interest and issuing a \$435,000 note payable resulting in a net increase of \$1,600,000 in equity during the period. This note receivable is in exchange for the issuance of 2,000,000 shares of the Company's common stock to a party unrelated to the Company, and that is fully secured by specific assets other than the equity instruments granted.

In October 2003 the Company conducted a \$50,000 private placement in which the Company issued 100,000 shares of common stock to an accredited investor at a price of \$0.50 per share. Also in October of 2003 the Company conducted a \$420,000 private placement in which the Company issued 700,000 shares of common stock to an accredited investor at a price of \$0.60 per share.

Note 20. Recent Accounting Pronouncements

In June 2001, the Financial Accounting Standards Board ("FASB") issued SFAS No. 141 "Business Combinations." The Statement is to be adopted for all business combinations initiated after June 30, 2001. The adoption of this statement did not impact the Company's financial position, results of operations, or cash flows.

In June 2001, the FASB issued SFAS No. 142 "Accounting for Goodwill and Intangible Assets." In accordance with certain provisions of the Statement, goodwill acquired after June 30, 2001 is not amortized. All provisions of the Statement are required to be applied in the fiscal year beginning after December 15, 2001. The adoption of this statement did not impact the Company's financial position, results of operations, or cash flows.

In August 2001, the FASB issued SFAS No. 143, "Accounting for Asset Retirement Obligations." SFAS No. 143 establishes accounting standards for recognition and measurement of a liability for an asset retirement obligation and the associated asset retirement cost. The Company adopted this statement for the year ending December 31, 2002. The adoption of this statement did not impact the Company's financial position, results of operations, or cash flows.

In July 2001, the FASB issued SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets which is effective for fiscal years beginning after December 15, 2001. SFAS 144 addresses financial accounting and reporting

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

for the impairment or disposal of long-lived assets and establishes a single accounting model, based on the framework established in SFAS 121, for long lived assets to be disposed of by sale. The adoption of this statement did not impact the Company's financial position, results of operations, or cash flows.

In April 2002, the FASB issued SFAS No. 145, "Rescission of FASB Statements No. 4, 44 and 64, Amendment of FASB Statement No. 13 and Technical Corrections". SFAS 145, which is effective for fiscal years beginning after May 15, 2002, provides guidance for income statement classification of gains and losses on extinguishments of debt and accounting for certain lease modifications that have economic effects that are similar to sale-leaseback transactions. The adoption of this statement did not impact the Company's financial position, results of operations, or cash flows.

In June 2002, the FASB issued SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities." SFAS 146 nullifies the guidance of the Emerging Issues Task Force (EITF) Issue No. 94-3, "Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring)." SFAS 146 requires that a liability for a cost that is associated with an exit or disposal activity be recognized when the liability is incurred. SFAS 146 also establishes that fair value is the objective for the initial measurement of the liability. The provisions of SFAS 146 are required for exit or disposal activities that are initiated after December 31, 2002. The adoption of this statement did not impact the Company's financial position, results of operations, or cash flows.

In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure". SFAS 148 amends FASB Statement No. 123, "Accounting for Stock-Based Compensation", to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, this Statement amends the disclosure requirements of Statement 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on the reported results. The provisions of SFAS 148 are effective for financial statements for fiscal years ending after December 15, 2002. The adoption of this statement did not impact the Company's financial position, results of operations, or cash flows.

In November 2002, the FASB issued FIN 45, which expands previously issued accounting guidance and disclosure requirements for certain guarantees. Except as described in Note 8, the adoption of this statement did not impact the Company's financial position, results of operations, or cash flows.

In April 2003, the FASB issued SFAS No. 149 "Amendment of Statement 133 on Derivative Instruments and Hedging Activities", which amends and clarifies the accounting guidance on certain derivative instruments and hedging activities. SFAS 149 is generally effective for contracts entered into or modified after June 30, 2003 and hedging relationships designated after June 30, 2003. The adoption of this statement did not impact the Company's financial position, results of operations, or cash flows.

In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity." SFAS 150 establishes standards for how an issuer of equity (including the equity shares of any entity whose financial statements are included in the consolidated financial statements) classifies and measures on its balance sheet certain financial instruments with characteristics of both liabilities and equity. SFAS 150 is effective for financial instruments entered into or modified after May 31, 2003 and for existing financial instruments after July 1, 2003. The adoption of this statement did not impact the Company's financial position, results of

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

operations, or cash flows.

ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE None.

PART III

ITEM 9. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

The executive officers and directors of PURE Bioscience and their ages are as follows:

Name	Age	Position	Held Position Since
Michael L. Krall	51	President, CEO, Chairman, Director	1992
Gary Brownell, CPA	54	Treasurer CFO, Director	1996
Gene Auerbach	58	Chief Operating Officer	2002
Donna Singer	33	Executive Vice President, Director	1998
Dennis Atchley, Esq.	50	Secretary	1996
Greg Barnhill	49	Director	2001
Dennis Brovarone	47	Director	1996
Patrick Galuska	44	Director	1996
Eugene Peiser, PD	71	Director	1996

The Directors serve until their successors are elected by the shareholders. Vacancies on the Board of Directors may be filled by appointment of the majority of the continuing directors. The executive officers serve at the discretion of the Board of Directors except as subject to the employment agreement with Mr. Krall.

Business Experience

DENNIS B. ATCHLEY, ESQ. Mr. Atchley is the Secretary of PURE Bioscience and currently practices as a sole practitioner in Carlsbad, California handling corporate and business related litigation matters. A 1973 graduate of Loyola Marymount University in Los Angeles and a 1976 graduate of California Western School of Law in San Diego, California, Mr. Atchley is a member of the California Bar, the San Diego County Bar Association, and the Association of Business Trial Lawyers.

GENE AUERBACH Mr. Auerbach is the Chief Operating Officer of PURE Bioscience. Prior to joining the Company in June 2002, Mr. Auerbach served as Senior Vice President, Global Supply Chain for Estee Lauder Companies (NYSE: EL) in New York City. Previously, he served as Senior Vice President for Development and International Development at AutoZone (NYSE: AZO) in Memphis, Tennessee. Prior to joining AutoZone, Mr. Auerbach gained significant international experience as Regional Director, Asia for Dairy Farm International (Jardines), where he played a key role in the executive management of 1400 retail stores in eight countries, including supermarkets, drug stores, convenience stores and restaurants. Before joining Dairy Farm International, Mr. Auerbach held the position of Senior Vice President at Costco (NasdaqNM: COST) and, prior thereto, Executive Vice President for Price Club. Before joining Price Club/Costco, Mr. Auerbach served 22 years in the US Navy where he was, and still is, the youngest officer ever selected for Captain (O6) in the history of the Navy Supply Corps. Mr. Auerbach holds a BA degree in Business Administration from University of Washington and an MBA degree from Wharton School of Finance and Commerce.

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

GREGORY H. BARNHILL Mr. Barnhill is Managing Director of North American Equity Sales at Deutsche Bank Securities, Inc., Baltimore, MD. He joined the firm in 1975, following his graduation from Brown University with an AB degree in economics.

30

DENNIS BROVARONE Mr. Brovarone has been practicing corporate and securities law since 1986 and as a sole practitioner since 1990. He was elected to the Company's Board of Directors in April 1996. From January 3002 to the present, Mr. Brovarone serves on the Board of Directors of Shannon International Resources, Inc., a publicly held Nevada corporation. From December 1997 to April 2001, Mr. Brovarone served as the President and Chairman of the Board of Directors of Ethika Corporation, a publicly held, Mississippi corporation investment holding company with its office in Littleton, Colorado. From January 1995 to March 1998, Mr. Brovarone served as President (Chairman) of the Board of Directors of The Community Involved Charter School, a four year old K-12 public school located in Lakewood, Colorado, operating under an independent charter and serving approximately 350 students in an individualized, experiential learning environment. Prior to 1990, Mr. Brovarone served as in-house counsel to R.B. Marich, Inc., a Denver, Colorado based brokerage firm. Mr. Brovarone lives and works in Littleton, Colorado.

GARY W. BROWNELL Mr. Brownell is a Certified Public Accountant in a private partnership practice. He is the partner in charge of taxes and municipal audits for his firm. Mr. Brownell graduated from San Diego State University in 1973 with a Bachelor of Science degree in accounting. He received his Certified Public Accountant designation in 1983. Mr. Brownell has been a partner in Brownell and Duffy since 1985.

PATRICK GALUSKA Mr. Galuska is a consulting petroleum engineer in Denver, Colorado. His practice focuses mainly on the acquisition and exploitation of underdeveloped oil and gas assets in the Rocky Mountain area. He is a Registered Professional Engineer and is a member of the Society of Petroleum Engineers. Mr. Galuska earned his BS degree in petroleum engineering from the University of Wyoming and received his MBA degree in Finance from the University of Denver. Mr. Galuska resides in Littleton, Colorado with his wife and two children.

MICHAEL L. KRALL Mr. Krall is the President, CEO and Chairman of the Board of Directors of PURE Bioscience, a position he has held since 1993. He is responsible for the strategic planning, product development, and day-to-day operations of PURE Bioscience. Previously, Mr. Krall was the President and CEO of Bettis-Krall Construction, Inc. a successful building-development company of custom homes and commercial property in San Diego County, California. He has also held numerous positions in general management in the hospitality industry. Mr. Krall attended Pepperdine University (economics, statistics, mechanical engineering). He previously served 4 years in the United States Marine Corps and was elected, by general election, to a 4 year term on the Valle de Oro Planning Board. Mr. Krall lives in El Cajon, California with his wife, Connie, and two children.

EUGENE S. PEISER, DOCTOR OF PHARMACY Dr. Peiser has been an independent consultant to FDA regulated industries since 1974 and a Member of the Board of PURE Bioscience since 1994. He graduated from the University of Tennessee College of Pharmacy with a Bachelor of Science in Pharmacy in 1951 and has received his Doctorate of Pharmacy. Dr. Peiser's consultancy advises on a wide variety of subjects, including compliance with the Prescription Drug Marketing Act and other government compliance matters, employee training and drug repackaging. Dr. Peiser furnishes expert witness services and has provided approved Pharmaceutical Continuing Education to several thousand attendees at

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

his seminars. Dr. Peiser is a Founding Director of the Association of Drug Repackagers; is appointed as a Registered Arbitrator by the American Registry of Arbitrators; and is President of the Southwest Chapter of the Association of Military Surgeons. Dr. Peiser lives and works in Palm Harbor, FL.

DONNA SINGER Ms. Singer is the Executive Vice President of PURE Bioscience. From 1996-1998, Ms. Singer served as Vice President of Operations for the Company. Ms. Singer is responsible for company operations, corporate communications, investor relations and marketing. Previously, Ms. Singer served as the investor relations executive at Western Garnet International, a Toronto Stock Exchange mining company. Ms. Singer graduated from Gonzaga University with a Bachelor of Arts degree and lives in El Cajon, California.

Committees: Meetings of the Board

We have a Compensation/Administration Committee and an Audit Committee. The Compensation/Administration Committee and the Audit Committee were formed in 1995. Messrs. Barnhill, Brovarone, Galuska and Peiser comprise the Compensation/Administration Committee and Messrs. Barnhill, Brownell, Galuska and Peiser are the Audit Committee. The Compensation/Administration Committee recommends to the Board the compensation of executive officers and will serve as the Administrative Committee for the Company's Stock Option Plans. The Audit Committee serves as a liaison between the Board and the Company's auditor. The Compensation/Administration Committee met once during the fiscal year ended July 31, 2003, and the Audit Committee met once during the fiscal year ended July 31, 2003.

Our Board of Directors held six meetings during the fiscal year ended July 31, 2003, at which time all the then Directors were present or consented in writing to the action taken at such meetings. No incumbent Director attended fewer than 100% of said meetings.

Compliance with Section 16(a) of Securities Exchange Act of 1934

To our knowledge, during the fiscal year ended July 31, 2003, our Directors and Officers complied with all applicable Section 16(a) filing requirements. This statement is based solely on a review of the copies of such reports furnished to us by our Directors and Officers and their written representations that such reports accurately reflect all reportable transactions.

31

Family Relationships

There is no family relationship between any Director, executive or person nominated or chosen by PURE Bioscience to become a Director or executive officer.

Code of Ethics

We have not as yet adopted a Code of Ethics that applies to our principal executive officer and principal financial officer. The Company's recent focus has been codifying internal controls as required by the Sarbanes-Oxley Act. We intend to adopt a Code of Ethics during this fiscal year.

Transactions with Management

PURE Bioscience did not enter into any transactions with Management during the fiscal year ended July 31, 2002.

ITEM 10. EXECUTIVE COMPENSATION

Summary Compensation Table

The following table shows for the fiscal year ending July 31, 2003, the compensation awarded or paid by the Company to its Chief Executive Officer and any of the executive officers of the Company whose total salary and bonus exceeded \$100,000 during such year (The "Named Executive Officers"):

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

SUMMARY COMPENSATION TABLE						
Name and Principle Position	Year	Annual Compensation		Long Term Compensation		
		Salary (S)	Other Annual Compensation (\$)	Awards	Payouts	
				Securities Underlying Options (#)	All Other Compen	
Michael L. Krall President/CEO	2003	168,000	0	50,000 Common	0	
Michael L. Krall President/CEO	2002	144,000	0	150,000 Common	0	
Michael L. Krall President/CEO	2001	144,000	0	50,000 Common	0	

No other executive officer earned more than \$100,000 during the current fiscal year.

32

Option Grants in Last Fiscal Year			
Individual Grants			
Name	Number of Common Shares Underlying Options Granted (#)	% of Total Options Granted to Employees in Fiscal Year	Exercise (\$/Sh
Michael L. Krall President/CEO	50,000	11	.50

Aggregated Option Exercises in Last Fiscal Year and Fiscal Year End
Option/Values

The following table sets forth the number and value of the unexercised options held by each of the Named Executive Officers at July 31, 2003.

Aggregate Option Exercises in Last Fiscal Year and FY-End Option Values			
Shares	Value	Number of Securities Underlying	Value of Une

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

Name	Acquired on Exercise (#)	Realized at FY-End (\$)	Unexercised Options at FY-End (#) Exercisable/Unexercisable	Option Exercisa
Michael L. Krall President/CEO	0	0	731,250 Common Shares/Exercisable	48,000

- (1) Option value based on the difference between the exercise price of unexercised options and the average closing price of \$0.74 for the 30 trading days ending July 31, 2003.

Employment Agreements and Executive Compensation

In April 1996, the Board of Directors approved a five-year employment agreement for Michael Krall, its President. Mr. Krall receives a salary of \$168,000 per year plus an amount equal to 3% of PURE Bioscience's net income before taxes, if any, plus other benefits. The Board of Directors has extended Mr. Krall's employment agreement for an additional year.

Compensation of Directors

Directors are entitled to receive \$300 plus reimbursement for all out-of-pocket expenses incurred for attendance at Board of Directors meetings.

Other Arrangements

1996 Directors And Officers Stock Option Plan: On April 17, 1996, the Company's Board of Directors approved a Directors and Officers Stock Option Plan. The purpose of the Plan is to advance the business and development of the Company and its shareholders by affording to the Directors and Officers of the Company who are ineligible to participate in the above Incentive Stock Option Plan, the opportunity to acquire a propriety interest in the Company by the grant of Options to acquire shares of the Company's common stock. The Plan is administered by the entire Board of Directors. The Plan became effective on April 17, 1996 by the Board of Directors, was not subject to Shareholder approval and shall terminate on April 17, 2006. Subject to anti-dilution provisions, the Plan may issue Options to acquire up to 1,000,000 shares to Directors and Officers. The maximum number of shares subject to Options granted to any one Director or Officer shall not exceed 200,000 shares in any 12-month period. The exercise price for Options shall be set by the Board of Directors but shall not be for less than eighty-five (85%) of the fair market value per share on the date of grant. The period in which Options can be exercised shall be set by the Board of Directors not to exceed five years from the date of Grant. The Plan may be terminated, modified or amended by the Board of Directors.

The PURE Bioscience 1998 Directors And Officers Stock Option Plan: On December 19, 1998, the Company's Shareholders approved the Amended PURE Bioscience 1998 Officers and Directors Stock Option Plan. The purpose of the Plan is to advance the business and development of the Company and its shareholders by affording to the Directors and Officers of the Company the opportunity to acquire a propriety interest in the Company by the grant of Options to acquire shares of the Company's common stock.

The PURE Bioscience 2001 Directors And Officers Stock Option Plan: On January 8, 2001, the Company's Shareholders approved the PURE Bioscience 2001 Officers and Directors Stock Option Plan. The purpose of the Plan is to advance the business and development of the Company and its shareholders by affording to the Directors and Officers of the Company the opportunity to acquire a propriety interest in the Company by the grant of Options to acquire shares of the Company's common stock.

The PURE Bioscience 2002 Non-Qualified Stock Option Plan: On March 11, 2002, the Company's Shareholders approved the PURE Bioscience 2002- Non-Qualified Stock Option Plan. The purpose of the Plan is to advance the business and development of the Company and its shareholders by affording Eligible Plan Participants the opportunity to acquire a propriety interest in the Company by the grant of Options to acquire shares of the Company's common stock. Eligible Plan Participants include the Directors and Officers of the Company, consultants, advisors and other individuals deemed by the Compensation Committee to provide valuable services to the Company but who are not otherwise eligible to participate in the Employee Incentive Stock Option Plan.

The Options granted are not "Incentive Stock Options" within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended. The issuance of such non-qualified options pursuant to this Plan is not expected to be a taxable event for the recipient until such time that the recipient elects to exercise the option whereupon the recipient is expected to recognize income to the extent the market price of the shares exceeds the exercise price of the option on the date of exercise.

The Plans are administered by an Administrative Committee whom shall serve a one year term. The Administrative Committee is composed of the Board's Compensation/Administration Committee. Subject to anti-dilution provisions, each Plan may issue Options to acquire up to 2,000,000 shares to Directors and Officers. The exercise price for Options shall be set by the Administrative Committee but shall not be for less than the fair market value of the shares on the date the Option is granted. Fair market value shall mean the average of the closing price for ten consecutive trading days at which the Stock is listed in the NASDAQ quotation system ending on the day prior to the date an Option is granted. The period in which Options can be exercised shall be set by the Administrative Committee not to exceed five years from the date of Grant. Options granted to new executive officers or directors shall vest one year from date of appointment or election. Shares issuable under options granted to continuing officers or directors are immediately exercisable and vest upon exercise. The maximum number of shares subject to Options granted to any one Director or Officer shall not exceed 200,000 shares in any 12-month period.

The Executive Officers and Directors of the Company are eligible to participate in the Plans. The Administrative Committee first granted the Executive Officers and Directors an option to purchase 100,000 shares of common stock at \$1.00 per share in 1998. The Administrative Committee shall grant to individuals newly appointed as Executive Officers or as Directors, an option to purchase 100,000 shares of common stock at fair market value. Upon each subsequent anniversary thereof, each such Officer and Director will receive an option to purchase 50,000 shares of common stock at fair market value. The Plans also give the Administrative Committee discretion to award additional options. The aggregate number and kind of shares within the Plans and the rights under outstanding Options granted hereunder, both as to the number of shares and Option price, will be adjusted accordingly in the event of a reverse split in the outstanding shares of the Common Stock of the Company.

The Board may at any time terminate the Plans. The approval of the majority of shareholders is required to increase the total number of shares subject to the Plans, change the manner of determining the option price or to withdraw the administration of the Plans from the Administrative Committee.

Termination of Employment and Change of Control Arrangement

There is no compensatory plan or arrangement with respect to any individual named above which results or will result from the resignation, retirement or any other termination of employment with the Company, or from a change in the

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

control of the Company.

34

ITEM 11. Security Ownership of Certain Beneficial Owners and of Management

The following table sets forth the number of shares of the Company's Common Stock beneficially owned as of February 19, 2004 by individual directors and executive officers and by all directors and executive officers of the Company as a group. Based upon a review of the Company's shareholders list as of February 19, 2004, there are two other registered holders of five percent or more of the Company's Common Stock. As of February 19, 2004 there were 13,854,088 shares outstanding.

Name and Address of Beneficial Owner	Title	Common Stock Ownership	Percentage of Shares Outstanding (%)
Dennis Atchley 1725 Gillespie Way El Cajon, CA 92020	Secretary	243,860 (1)	1.76
Gene Auerbach 1725 Gillespie Way El Cajon, CA 92020	Chief Operating Officer	175,000 (2)	1.26
Gregory Barnhill 1725 Gillespie Way El Cajon, CA 92020	Director	425,000 (3)	3.07
Dennis Brovarone 1725 Gillespie Way El Cajon, CA 92020	Director	506,483 (4)	3.66
Gary Brownell 1725 Gillespie Way El Cajon, CA 92020	Treasurer, CFO/Director	450,321 (5)	3.25
Patrick Galuska 1725 Gillespie Way El Cajon, CA 92020	Director	420,690 (6)	3.04
Michael L. Krall 1725 Gillespie Way El Cajon, CA 92020	President, CEO/Chairman	1,353,560 (7)	9.77
Eugene Peiser 1725 Gillespie Way El Cajon, CA 92020	Director	476,136 (8)	3.44
Donna Singer 1725 Gillespie Way El Cajon, CA 92020	Executive VP, Director	403,356 (9)	2.91

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

Directors and Officers as a Group (9 individuals)	4,454,406 (10)	32.15
Next9, LLC 850 State Street San Diego, CA 92101	2,000,000 (11)	14.44
Jeffery P. Dauenhauer 800 5th Ave., Suite 4100 Seattle WA, 98104	700,000	5.05

- (1) Includes presently exercisable options to acquire up to 200,000 shares.
- (2) Includes presently exercisable options to acquire up to 150,000 shares.
- (3) Includes presently exercisable options to acquire up to 250,000 shares.
- (4) Includes presently exercisable options to acquire up to 435,000 shares.
- (5) Includes presently exercisable options to acquire up to 400,000 shares.
- (6) Includes presently exercisable options to acquire up to 350,000 shares.
- (7) Includes presently exercisable options to acquire up to 731,250 shares.
- (8) Includes presently exercisable options to acquire up to 400,000 shares.
- (9) Includes presently exercisable options to acquire up to 375,000 shares.
- (10) Includes presently exercisable options held by all of the above officers and directors to acquire up to 2,814,250 shares.
- (11) Lee Brukman is the control person of Next9, LLC.

Securities Authorized for Issuance under Equity Compensation Plans

Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)	Weighted-average exercise price of outstanding options, warrants and rights (b)	Number of securities remaining available for future issuance (excluding securities reflected in column (c)) (c)
Equity compensation plans approved by security holders	3,129,375	1.86	5,987,278
Equity compensation plans not approved by security holders	1,015,000	1.63	533,000
Total	4,144,375	1.83	6,520,278

The following equity compensation plans were not approved by security holders:

1. 2001 ETIH20 Stock Option Plan: Adopted by the Board in January 2001 with 1,000,000 shares authorized under this Plan. The options have a five-year term with vesting ratably over a five-year period.
2. 2001 Consultants and Advisors Stock Option Plan: Adopted by the Board in January 2001 with 500,000 shares authorized under this Plan. The maximum number of shares subject to options granted under this Plan to

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

any one participant shall not exceed 50,000 shares in any 12-month period. The options have a five-year term with vesting ratably over a five-year period.

3. Executive Officers and Directors are not eligible participants under these plans.

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
None.

ITEM 13. EXHIBITS. The following Exhibits are filed as part of this registration statement pursuant to Item 601 of Regulation S-B:

- 3.1 (1) -- Articles of Incorporation, Articles of Amendment and Bylaws
 - 3.1.1 (2) -- Articles of Amendment dated March 11, 2002
 - 3.1.2 -- Articles of Amendment dated October 6, 2003
 - 4.1 (1) -- Form of Class A Warrant
 - 4.2 (1) -- Form of Class Z Warrant
 - 4.3 (1) -- Form of Common Stock Certificate
 - 4.4 (1) -- Warrant Agreement
 - 4.5 (3) -- March 2000 Warrant
 - 4.6 (4) -- January 2001 Warrant
 - 4.7 (5) -- Convertible Debenture
 - 4.8 (6) -- Convertible Debenture Purchase Agreement
 - 4.9 (7) -- Convertible Debenture Warrant
 - 10.1 (1) -- Employment Contract/Michael L. Krall
 - 10.2 (8) -- Manufacturing, Licensing and Distribution Agreement dated March 26, 2001
 - 10.3 (9) -- Axenohl License Agreement
 - 10.4 (10) -- Weaver - Roach X Assignment
 - 10.5 (10) -- Dodo Agreement [Confidential treatment requested for certain omitted information filed separately.]
 - 10.6 (9) -- Promissory Note of Michael Krall
 - 10.7 (9) -- Promissory Note of Gary Brownell
 - 10.8 (10) -- Nutripure Dealer Agreement
 - 10.9 (10) -- Sales Finance Agreement
 - 10.10 (11) -- ETIH2O, Inc., Acquisition Agreement
 - 10.11 (12) -- NVID Litigation Settlement Agreement
 - 10.12 (13) -- Addendum #1 to NVID Settlement Agreement
 - 10.13 (14) -- Therapeutics, Inc. Agreement [Confidential treatment requested for certain omitted information filed separately.]
 - 21 (15) -- Subsidiaries of the Registrant
 - 31.1 -- Sarbanes Oxley 302 Certification - CEO
 - 31.2 -- Sarbanes Oxley 302 Certification - CFO
 - 32.1 -- Sarbanes Oxley 906 Certification - CEO
 - 32.2 -- Sarbanes Oxley 906 Certification - CFO
-
- (1) Incorporated by reference from Form SB-2 registration statement, SEC File # 333-00434 effective August 8, 1996
 - (2) Incorporated by reference from the Annual Report on Form 10KSB for the fiscal year ended July 31, 2002 filed on October 29, 2002.
 - (3) Incorporated by reference from S-3 registration statement, SEC File #333-36248 effective on May 17, 2000
 - (4) Incorporated by reference from S-3 registration statement, SEC File #333-55758 effective on February 26, 2001
 - (5) Incorporated by reference from S-3 registration statement, SEC File #333-61664 filed on May 25, 2001
 - (6) Incorporated by reference from pre-effective amendment no. 1 to S-3 registration statement, SEC File #333-61664 filed on July 10, 2001

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

- (7) Incorporated by reference from pre-effective amendment no. 2 to S-3 registration statement, SEC File #333-61664 filed on August 13, 2001
- (8) Incorporated by reference from Current Report on Form 8-K filed on May 24, 2001 as amended on October 19, 2001
- (9) Incorporated by reference from the Amended Annual Report on Form 10KSB for the fiscal year ended July 31, 2000 filed on October 19, 2001
- (10) Incorporated by reference from Amended Form 10QSB for the nine month period ended April 30, 2001 filed on October 19, 2001
- (11) Incorporated by reference from the Amended Annual Report on Form 10KSB for the fiscal year ended July 31, 2001 filed on November 13, 2001
- (12) Incorporated by reference from Current Report on Form 8-K filed on December 6, 2001
- (13) Incorporated by reference from Amended Current Report on Form 8-K filed on December 7, 2001
- (14) Incorporated by reference from Amended Annual Report on Form 10-KSB for the fiscal year ended July 31, 2003 filed on January 30, 2004
- (15) Incorporated by reference from Annual Report on Form 10-KSB for the fiscal year ended July 31, 2003 filed on October 29, 2003.

B. Reports on Form 8-K: No Reports on Form 8-K were filed during the fourth quarter of the fiscal year.

35

ITEM 14. CONTROLS AND PROCEDURES

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based closely on the definition of "disclosure controls and procedures" in Rule 13a-14(c). In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As of the end of the period, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and the Company's Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based on the foregoing, the Company's Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective.

There have been no significant changes in the Company's internal controls or in other factors that could significantly affect the internal controls subsequent to the date the Company completed its evaluation.

ITEM 15. PRINCIPAL ACCOUNTANT FEES AND SERVICES

Miller & McCollom, Certified Public Accountants, are the Company's independent auditors to examine the financial statements of the Company for the fiscal year ending July 31, 2003. Miller & McCollom has performed the following services and

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

has been paid the following fees for these fiscal years.

Audit Fees

Miller & McCollom was paid aggregate fees of \$39,312 for the fiscal year ended July 31, 2002 and \$70,457 for the fiscal year ended July 31, 2003 for professional services rendered for the audit of the Company's annual financial statements and for the reviews of the financial statements included in Company's quarterly reports on Form 10QSB during these fiscal years.

Audit -Related Fees

Miller & McCollom was not paid any additional fees for the fiscal year ended July 31, 2002 and July 31, 2003 for assurance and related services reasonably related to the performance of the audit or review of the Company's financial statements.

Tax Fees

Miller & McCollom was paid aggregate fees of \$15,450 for the fiscal year ended July 31, 2002 and \$10,900 for the fiscal year ended July 31, 2003 for professional services rendered for tax compliance, tax advice and tax planning.

Other Fees

Miller & McCollom was paid no other fees for professional services during the fiscal years ended July 31, 2002 and July 31, 2003.

36

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PURE BIOSCIENCE

DATE

/s/ MICHAEL L. KRALL

February 19,2004

Michael L. Krall, Chairman/President/CEO

Pursuant to the requirements of the Securities Exchange Act of 1934, this report is signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

NAME	TITLE	DATE
/s/ GREGORY BARNHILL ----- Gregory Barnhill	Director	February 19 -----
/s/ DENNIS BROVARONE ----- Dennis Brovarone	Director	February 19 -----

Edgar Filing: PURE BIOSCIENCE - Form 10KSB/A

/s/ GARY BROWNELL ----- Gary Brownell	Chief Financial Officer and Director	February 19 -----
/s/ PATRICK GALUSKA ----- Patrick Galuska	Director	February 19 -----
/s/ MICHAEL L. KRALL ----- Michael L. Krall	President/CEO and Director	February 19 -----
/s/ EUGENE PEISER ----- Eugene Peiser	Director	February 19 -----
/s/ DONNA SINGER ----- Donna Singer	Executive Vice President and Director	February 19 -----